<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230002483</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>289</s160></s100><s200><s210>1</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 1Thr Gly Met Asn Ser Asn Ile Gly Ala Gly Tyr Asp Val Tyr1               5                   10</s400><s200><s210>2</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 2Gly Asn Ser Asn Arg Pro Ser1               5</s400><s200><s210>3</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 3Gln Ser Tyr Asp Thr Ser Leu Asn Gly Trp Ala1               5                   10</s400><s200><s210>4</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 4Asp His Ala Met Ser1               5</s400><s200><s210>5</s210><s211>19</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 5Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala Ala1               5                   10                  15Val Arg Gly</s400><s200><s210>6</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 6Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr Gly Met Asp Val1               5                   10                  15</s400><s200><s210>7</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 7Thr Gly Met Asn Ser Asn Ile Gly Ala Gly Tyr Asp Val Tyr1               5                   10</s400><s200><s210>8</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 8Gly Asn Ser Asn Arg Pro Ser1               5</s400><s200><s210>9</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 9Gln Ser Tyr Asp Thr Ser Leu Asn Gly Trp Ala1               5                   10</s400><s200><s210>10</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 10Asp His Ala Met Ser1               5</s400><s200><s210>11</s210><s211>19</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 11Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala Ala1               5                   10                  15Val Arg Gly</s400><s200><s210>12</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 12Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr Gly Met Asp Val1               5                   10                  15</s400><s200><s210>13</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 13Glu Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Arg Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110</s400><s200><s210>14</s210><s211>127</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 14Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Pro Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>15</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 15gagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa gagcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggc                              336</s400><s200><s210>16</s210><s211>381</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 16gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60ccctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc a                                              381</s400><s200><s210>17</s210><s211>217</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 17Glu Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Arg Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu        115                 120                 125Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val Ser Asp Phe    130                 135                 140Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val145                 150                 155                 160Lys Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys                165                 170                 175Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser            180                 185                 190His Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser Thr Val Glu        195                 200                 205Lys Thr Val Ala Pro Ala Glu Cys Ser    210                 215</s400><s200><s210>18</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 18Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Pro Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>19</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 19Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Pro Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>20</s210><s211>651</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 20gagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa gagcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggccagc ccaaggctgc cccctcggtc    360actctgttcc caccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc    420gtaagtgact tctacccggg agccgtgaca gtggcctgga aggcagatgg cagccccgtc    480aaggtgggag tggagaccac caaaccctcc aaacaaagca acaacaagta tgcggccagc    540agctacctga gcctgacgcc cgagcagtgg aagtcccaca gaagctacag ctgccgggtc    600acgcatgaag ggagcaccgt ggagaagaca gtggcccctg cagaatgctc t             651</s400><s200><s210>21</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 21gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60ccctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag   1320gctctgcaca accactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>22</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 22gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60ccctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gctgcatgag   1320gctctgcact cccactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>23</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 23Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110</s400><s200><s210>24</s210><s211>127</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 24Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>25</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 25cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggc                              336</s400><s200><s210>26</s210><s211>381</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 26gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc a                                              381</s400><s200><s210>27</s210><s211>217</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 27Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu        115                 120                 125Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val Ser Asp Phe    130                 135                 140Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val145                 150                 155                 160Lys Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys                165                 170                 175Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser            180                 185                 190His Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser Thr Val Glu        195                 200                 205Lys Thr Val Ala Pro Ala Glu Cys Ser    210                 215</s400><s200><s210>28</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 28Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>29</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 29Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>30</s210><s211>651</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 30cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggccagc ccaaggctgc cccctcggtc    360actctgttcc caccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc    420gtaagtgact tctacccggg agccgtgaca gtggcctgga aggcagatgg cagccccgtc    480aaggtgggag tggagaccac caaaccctcc aaacaaagca acaacaagta tgcggccagc    540agctacctga gcctgacgcc cgagcagtgg aagtcccaca gaagctacag ctgccgggtc    600acgcatgaag ggagcaccgt ggagaagaca gtggcccctg cagaatgctc t             651</s400><s200><s210>31</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 31gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag   1320gctctgcaca accactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>32</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 32gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gctgcatgag   1320gctctgcact cccactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>33</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 33Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110</s400><s200><s210>34</s210><s211>127</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 34Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>35</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 35cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggc                              336</s400><s200><s210>36</s210><s211>381</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 36gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc a                                              381</s400><s200><s210>37</s210><s211>217</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 37Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu        115                 120                 125Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val Ser Asp Phe    130                 135                 140Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val145                 150                 155                 160Lys Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys                165                 170                 175Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser            180                 185                 190His Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser Thr Val Glu        195                 200                 205Lys Thr Val Ala Pro Ala Glu Cys Ser    210                 215</s400><s200><s210>38</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 38Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>39</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 39Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>40</s210><s211>651</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 40cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggccagc ccaaggctgc cccctcggtc    360actctgttcc caccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc    420gtaagtgact tctacccggg agccgtgaca gtggcctgga aggcagatgg cagccccgtc    480aaggtgggag tggagaccac caaaccctcc aaacaaagca acaacaagta tgcggccagc    540agctacctga gcctgacgcc cgagcagtgg aagtcccaca gaagctacag ctgccgggtc    600acgcatgaag ggagcaccgt ggagaagaca gtggcccctg cagaatgctc t             651</s400><s200><s210>41</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 41gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag   1320gctctgcaca accactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>42</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 42gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gctgcatgag   1320gctctgcact cccactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>43</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 43Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110</s400><s200><s210>44</s210><s211>127</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 44Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>45</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 45cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggc                              336</s400><s200><s210>46</s210><s211>381</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 46gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc a                                              381</s400><s200><s210>47</s210><s211>217</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 47Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu        115                 120                 125Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val Ser Asp Phe    130                 135                 140Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val145                 150                 155                 160Lys Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys                165                 170                 175Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser            180                 185                 190His Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser Thr Val Glu        195                 200                 205Lys Thr Val Ala Pro Ala Glu Cys Ser    210                 215</s400><s200><s210>48</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 48Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>49</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 49Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>50</s210><s211>651</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 50cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggccagc ccaaggctgc cccctcggtc    360actctgttcc caccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc    420gtaagtgact tctacccggg agccgtgaca gtggcctgga aggcagatgg cagccccgtc    480aaggtgggag tggagaccac caaaccctcc aaacaaagca acaacaagta tgcggccagc    540agctacctga gcctgacgcc cgagcagtgg aagtcccaca gaagctacag ctgccgggtc    600acgcatgaag ggagcaccgt ggagaagaca gtggcccctg cagaatgctc t             651</s400><s200><s210>51</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 51gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag   1320gctctgcaca accactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>52</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 52gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gctgcatgag   1320gctctgcact cccactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>53</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 53Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110</s400><s200><s210>54</s210><s211>127</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 54Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>55</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 55cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggc                              336</s400><s200><s210>56</s210><s211>381</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 56gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc a                                              381</s400><s200><s210>57</s210><s211>217</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 57Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu        115                 120                 125Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val Ser Asp Phe    130                 135                 140Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val145                 150                 155                 160Lys Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys                165                 170                 175Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser            180                 185                 190His Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser Thr Val Glu        195                 200                 205Lys Thr Val Ala Pro Ala Glu Cys Ser    210                 215</s400><s200><s210>58</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 58Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>59</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 59Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>60</s210><s211>651</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 60cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggccagc ccaaggctgc cccctcggtc    360actctgttcc caccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc    420gtaagtgact tctacccggg agccgtgaca gtggcctgga aggcagatgg cagccccgtc    480aaggtgggag tggagaccac caaaccctcc aaacaaagca acaacaagta tgcggccagc    540agctacctga gcctgacgcc cgagcagtgg aagtcccaca gaagctacag ctgccgggtc    600acgcatgaag ggagcaccgt ggagaagaca gtggcccctg cagaatgctc t             651</s400><s200><s210>61</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 61gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag   1320gctctgcaca accactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>62</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 62gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gctgcatgag   1320gctctgcact cccactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>63</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 63Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110</s400><s200><s210>64</s210><s211>127</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 64Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>65</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 65cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggc                              336</s400><s200><s210>66</s210><s211>381</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 66gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc a                                              381</s400><s200><s210>67</s210><s211>217</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 67Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu        115                 120                 125Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val Ser Asp Phe    130                 135                 140Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val145                 150                 155                 160Lys Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys                165                 170                 175Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser            180                 185                 190His Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser Thr Val Glu        195                 200                 205Lys Thr Val Ala Pro Ala Glu Cys Ser    210                 215</s400><s200><s210>68</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 68Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>69</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 69Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>70</s210><s211>651</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 70cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggccagc ccaaggctgc cccctcggtc    360actctgttcc caccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc    420gtaagtgact tctacccggg agccgtgaca gtggcctgga aggcagatgg cagccccgtc    480aaggtgggag tggagaccac caaaccctcc aaacaaagca acaacaagta tgcggccagc    540agctacctga gcctgacgcc cgagcagtgg aagtcccaca gaagctacag ctgccgggtc    600acgcatgaag ggagcaccgt ggagaagaca gtggcccctg cagaatgctc t             651</s400><s200><s210>71</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 71gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag   1320gctctgcaca accactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>72</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 72gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gctgcatgag   1320gctctgcact cccactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>73</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 73Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110</s400><s200><s210>74</s210><s211>127</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 74Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>75</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 75cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggc                              336</s400><s200><s210>76</s210><s211>381</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 76gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc a                                              381</s400><s200><s210>77</s210><s211>217</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 77Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu        115                 120                 125Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val Ser Asp Phe    130                 135                 140Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val145                 150                 155                 160Lys Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys                165                 170                 175Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser            180                 185                 190His Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser Thr Val Glu        195                 200                 205Lys Thr Val Ala Pro Ala Glu Cys Ser    210                 215</s400><s200><s210>78</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 78Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>79</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 79Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>80</s210><s211>651</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 80cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggccagc ccaaggctgc cccctcggtc    360actctgttcc caccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc    420gtaagtgact tctacccggg agccgtgaca gtggcctgga aggcagatgg cagccccgtc    480aaggtgggag tggagaccac caaaccctcc aaacaaagca acaacaagta tgcggccagc    540agctacctga gcctgacgcc cgagcagtgg aagtcccaca gaagctacag ctgccgggtc    600acgcatgaag ggagcaccgt ggagaagaca gtggcccctg cagaatgctc t             651</s400><s200><s210>81</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 81gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag   1320gctctgcaca accactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>82</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 82gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gctgcatgag   1320gctctgcact cccactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>83</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 83Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110</s400><s200><s210>84</s210><s211>127</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 84Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>85</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 85cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggc                              336</s400><s200><s210>86</s210><s211>381</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 86gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc a                                              381</s400><s200><s210>87</s210><s211>217</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 87Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu        115                 120                 125Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val Ser Asp Phe    130                 135                 140Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val145                 150                 155                 160Lys Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys                165                 170                 175Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser            180                 185                 190His Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser Thr Val Glu        195                 200                 205Lys Thr Val Ala Pro Ala Glu Cys Ser    210                 215</s400><s200><s210>88</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 88Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>89</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 89Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>90</s210><s211>651</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 90cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggccagc ccaaggctgc cccctcggtc    360actctgttcc caccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc    420gtaagtgact tctacccggg agccgtgaca gtggcctgga aggcagatgg cagccccgtc    480aaggtgggag tggagaccac caaaccctcc aaacaaagca acaacaagta tgcggccagc    540agctacctga gcctgacgcc cgagcagtgg aagtcccaca gaagctacag ctgccgggtc    600acgcatgaag ggagcaccgt ggagaagaca gtggcccctg cagaatgctc t             651</s400><s200><s210>91</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 91gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag   1320gctctgcaca accactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>92</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 92gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gctgcatgag   1320gctctgcact cccactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>93</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 93Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110</s400><s200><s210>94</s210><s211>127</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 94Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>95</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 95cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggc                              336</s400><s200><s210>96</s210><s211>381</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 96gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc a                                              381</s400><s200><s210>97</s210><s211>217</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 97Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu        115                 120                 125Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val Ser Asp Phe    130                 135                 140Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val145                 150                 155                 160Lys Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys                165                 170                 175Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser            180                 185                 190His Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser Thr Val Glu        195                 200                 205Lys Thr Val Ala Pro Ala Glu Cys Ser    210                 215</s400><s200><s210>98</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 98Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>99</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 99Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>100</s210><s211>651</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 100cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggccagc ccaaggctgc cccctcggtc    360actctgttcc caccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc    420gtaagtgact tctacccggg agccgtgaca gtggcctgga aggcagatgg cagccccgtc    480aaggtgggag tggagaccac caaaccctcc aaacaaagca acaacaagta tgcggccagc    540agctacctga gcctgacgcc cgagcagtgg aagtcccaca gaagctacag ctgccgggtc    600acgcatgaag ggagcaccgt ggagaagaca gtggcccctg cagaatgctc t             651</s400><s200><s210>101</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 101gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag   1320gctctgcaca accactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>102</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 102gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gctgcatgag   1320gctctgcact cccactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>103</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 103Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110</s400><s200><s210>104</s210><s211>127</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 104Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>105</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 105cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggc                              336</s400><s200><s210>106</s210><s211>381</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 106gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc a                                              381</s400><s200><s210>107</s210><s211>217</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 107Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu        115                 120                 125Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val Ser Asp Phe    130                 135                 140Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val145                 150                 155                 160Lys Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys                165                 170                 175Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser            180                 185                 190His Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser Thr Val Glu        195                 200                 205Lys Thr Val Ala Pro Ala Glu Cys Ser    210                 215</s400><s200><s210>108</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 108Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>109</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 109Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>110</s210><s211>651</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 110cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggccagc ccaaggctgc cccctcggtc    360actctgttcc caccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc    420gtaagtgact tctacccggg agccgtgaca gtggcctgga aggcagatgg cagccccgtc    480aaggtgggag tggagaccac caaaccctcc aaacaaagca acaacaagta tgcggccagc    540agctacctga gcctgacgcc cgagcagtgg aagtcccaca gaagctacag ctgccgggtc    600acgcatgaag ggagcaccgt ggagaagaca gtggcccctg cagaatgctc t             651</s400><s200><s210>111</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 111gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag   1320gctctgcaca accactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>112</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 112gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gctgcatgag   1320gctctgcact cccactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>113</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 113Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110</s400><s200><s210>114</s210><s211>127</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 114Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>115</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 115cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggc                              336</s400><s200><s210>116</s210><s211>381</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 116gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc a                                              381</s400><s200><s210>117</s210><s211>217</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 117Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu        115                 120                 125Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val Ser Asp Phe    130                 135                 140Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val145                 150                 155                 160Lys Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys                165                 170                 175Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser            180                 185                 190His Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser Thr Val Glu        195                 200                 205Lys Thr Val Ala Pro Ala Glu Cys Ser    210                 215</s400><s200><s210>118</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 118Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>119</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 119Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>120</s210><s211>651</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 120cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggccagc ccaaggctgc cccctcggtc    360actctgttcc caccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc    420gtaagtgact tctacccggg agccgtgaca gtggcctgga aggcagatgg cagccccgtc    480aaggtgggag tggagaccac caaaccctcc aaacaaagca acaacaagta tgcggccagc    540agctacctga gcctgacgcc cgagcagtgg aagtcccaca gaagctacag ctgccgggtc    600acgcatgaag ggagcaccgt ggagaagaca gtggcccctg cagaatgctc t             651</s400><s200><s210>121</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 121gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag   1320gctctgcaca accactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>122</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 122gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gctgcatgag   1320gctctgcact cccactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>123</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 123Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110</s400><s200><s210>124</s210><s211>127</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 124Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>125</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 125cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggc                              336</s400><s200><s210>126</s210><s211>381</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 126gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc a                                              381</s400><s200><s210>127</s210><s211>217</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 127Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu        115                 120                 125Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val Ser Asp Phe    130                 135                 140Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val145                 150                 155                 160Lys Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys                165                 170                 175Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser            180                 185                 190His Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser Thr Val Glu        195                 200                 205Lys Thr Val Ala Pro Ala Glu Cys Ser    210                 215</s400><s200><s210>128</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 128Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>129</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 129Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>130</s210><s211>651</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 130cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggccagc ccaaggctgc cccctcggtc    360actctgttcc caccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc    420gtaagtgact tctacccggg agccgtgaca gtggcctgga aggcagatgg cagccccgtc    480aaggtgggag tggagaccac caaaccctcc aaacaaagca acaacaagta tgcggccagc    540agctacctga gcctgacgcc cgagcagtgg aagtcccaca gaagctacag ctgccgggtc    600acgcatgaag ggagcaccgt ggagaagaca gtggcccctg cagaatgctc t             651</s400><s200><s210>131</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 131gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag   1320gctctgcaca accactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>132</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 132gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gctgcatgag   1320gctctgcact cccactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>133</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 133Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110</s400><s200><s210>134</s210><s211>127</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 134Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>135</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 135cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggc                              336</s400><s200><s210>136</s210><s211>381</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 136gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc a                                              381</s400><s200><s210>137</s210><s211>217</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 137Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu        115                 120                 125Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val Ser Asp Phe    130                 135                 140Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val145                 150                 155                 160Lys Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys                165                 170                 175Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser            180                 185                 190His Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser Thr Val Glu        195                 200                 205Lys Thr Val Ala Pro Ala Glu Cys Ser    210                 215</s400><s200><s210>138</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 138Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>139</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 139Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>140</s210><s211>651</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 140cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggccagc ccaaggctgc cccctcggtc    360actctgttcc caccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc    420gtaagtgact tctacccggg agccgtgaca gtggcctgga aggcagatgg cagccccgtc    480aaggtgggag tggagaccac caaaccctcc aaacaaagca acaacaagta tgcggccagc    540agctacctga gcctgacgcc cgagcagtgg aagtcccaca gaagctacag ctgccgggtc    600acgcatgaag ggagcaccgt ggagaagaca gtggcccctg cagaatgctc t             651</s400><s200><s210>141</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 141gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag   1320gctctgcaca accactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>142</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 142gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gctgcatgag   1320gctctgcact cccactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>143</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 143Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110</s400><s200><s210>144</s210><s211>127</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 144Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>145</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 145cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggc                              336</s400><s200><s210>146</s210><s211>381</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 146gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc a                                              381</s400><s200><s210>147</s210><s211>217</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 147Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu        115                 120                 125Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val Ser Asp Phe    130                 135                 140Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val145                 150                 155                 160Lys Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys                165                 170                 175Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser            180                 185                 190His Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser Thr Val Glu        195                 200                 205Lys Thr Val Ala Pro Ala Glu Cys Ser    210                 215</s400><s200><s210>148</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 148Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>149</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 149Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>150</s210><s211>651</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 150cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggccagc ccaaggctgc cccctcggtc    360actctgttcc caccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc    420gtaagtgact tctacccggg agccgtgaca gtggcctgga aggcagatgg cagccccgtc    480aaggtgggag tggagaccac caaaccctcc aaacaaagca acaacaagta tgcggccagc    540agctacctga gcctgacgcc cgagcagtgg aagtcccaca gaagctacag ctgccgggtc    600acgcatgaag ggagcaccgt ggagaagaca gtggcccctg cagaatgctc t             651</s400><s200><s210>151</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 151gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag   1320gctctgcaca accactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>152</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 152gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gctgcatgag   1320gctctgcact cccactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>153</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 153Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110</s400><s200><s210>154</s210><s211>127</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 154Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>155</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 155cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggc                              336</s400><s200><s210>156</s210><s211>381</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 156gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc a                                              381</s400><s200><s210>157</s210><s211>217</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 157Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu        115                 120                 125Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val Ser Asp Phe    130                 135                 140Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val145                 150                 155                 160Lys Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys                165                 170                 175Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser            180                 185                 190His Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser Thr Val Glu        195                 200                 205Lys Thr Val Ala Pro Ala Glu Cys Ser    210                 215</s400><s200><s210>158</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 158Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>159</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 159Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>160</s210><s211>651</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 160cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggccagc ccaaggctgc cccctcggtc    360actctgttcc caccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc    420gtaagtgact tctacccggg agccgtgaca gtggcctgga aggcagatgg cagccccgtc    480aaggtgggag tggagaccac caaaccctcc aaacaaagca acaacaagta tgcggccagc    540agctacctga gcctgacgcc cgagcagtgg aagtcccaca gaagctacag ctgccgggtc    600acgcatgaag ggagcaccgt ggagaagaca gtggcccctg cagaatgctc t             651</s400><s200><s210>161</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 161gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag   1320gctctgcaca accactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>162</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 162gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gctgcatgag   1320gctctgcact cccactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>163</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 163Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110</s400><s200><s210>164</s210><s211>127</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 164Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>165</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 165cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggc                              336</s400><s200><s210>166</s210><s211>381</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 166gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc a                                              381</s400><s200><s210>167</s210><s211>217</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 167Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu        115                 120                 125Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val Ser Asp Phe    130                 135                 140Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val145                 150                 155                 160Lys Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys                165                 170                 175Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser            180                 185                 190His Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser Thr Val Glu        195                 200                 205Lys Thr Val Ala Pro Ala Glu Cys Ser    210                 215</s400><s200><s210>168</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 168Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>169</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 169Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>170</s210><s211>651</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 170cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggccagc ccaaggctgc cccctcggtc    360actctgttcc caccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc    420gtaagtgact tctacccggg agccgtgaca gtggcctgga aggcagatgg cagccccgtc    480aaggtgggag tggagaccac caaaccctcc aaacaaagca acaacaagta tgcggccagc    540agctacctga gcctgacgcc cgagcagtgg aagtcccaca gaagctacag ctgccgggtc    600acgcatgaag ggagcaccgt ggagaagaca gtggcccctg cagaatgctc t             651</s400><s200><s210>171</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 171gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag   1320gctctgcaca accactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>172</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 172gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gctgcatgag   1320gctctgcact cccactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>173</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 173Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110</s400><s200><s210>174</s210><s211>127</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 174Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>175</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 175cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggc                              336</s400><s200><s210>176</s210><s211>381</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 176gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc a                                              381</s400><s200><s210>177</s210><s211>217</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 177Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu        115                 120                 125Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val Ser Asp Phe    130                 135                 140Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val145                 150                 155                 160Lys Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys                165                 170                 175Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser            180                 185                 190His Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser Thr Val Glu        195                 200                 205Lys Thr Val Ala Pro Ala Glu Cys Ser    210                 215</s400><s200><s210>178</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 178Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>179</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 179Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr His Tyr Ala Ala    50                  55                  60Ala Val Arg Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Ala Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Ala Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>180</s210><s211>651</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 180cagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa ctgcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct gaatggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggccagc ccaaggctgc cccctcggtc    360actctgttcc caccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc    420gtaagtgact tctacccggg agccgtgaca gtggcctgga aggcagatgg cagccccgtc    480aaggtgggag tggagaccac caaaccctcc aaacaaagca acaacaagta tgcggccagc    540agctacctga gcctgacgcc cgagcagtgg aagtcccaca gaagctacag ctgccgggtc    600acgcatgaag ggagcaccgt ggagaagaca gtggcccctg cagaatgctc t             651</s400><s200><s210>181</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 181gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag   1320gctctgcaca accactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>182</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 182gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60agctgtgcgg cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180cactacgccg cggctgtgag aggcagattc accatctcgc gagatgattc taaaagcact    240gtctatctgc aaatgaacag cctgaaagca gaggacacag ccgtgtattt ctgtgctaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gctgcatgag   1320gctctgcact cccactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>183</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 183Thr Gly Met Asn Ser Asn Ile Gly Ala Gly Tyr Asp Val Tyr1               5                   10</s400><s200><s210>184</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 184Gly Asn Ser Asn Arg Pro Ser1               5</s400><s200><s210>185</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 185Gln Ser Tyr Asp Thr Ser Leu Asp Gly Trp Ala1               5                   10</s400><s200><s210>186</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 186Asp His Ala Met Ser1               5</s400><s200><s210>187</s210><s211>19</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 187Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr Lys Tyr Ala Ala Ala1               5                   10                  15Val Lys Gly</s400><s200><s210>188</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 188Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr Gly Met Asp Val1               5                   10                  15</s400><s200><s210>189</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 189Thr Gly Met Asn Ser Asn Ile Gly Ala Gly Tyr Asp Val Tyr1               5                   10</s400><s200><s210>190</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 190Gly Asn Ser Asn Arg Pro Ser1               5</s400><s200><s210>191</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 191Gln Ser Tyr Asp Thr Ser Leu Asp Gly Trp Ala1               5                   10</s400><s200><s210>192</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 192Asp His Ala Met Ser1               5</s400><s200><s210>193</s210><s211>19</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 193Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr Lys Tyr Ala Ala Ala1               5                   10                  15Val Lys Gly</s400><s200><s210>194</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 194Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr Gly Met Asp Val1               5                   10                  15</s400><s200><s210>195</s210><s211>112</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 195Glu Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Arg Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asp Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110</s400><s200><s210>196</s210><s211>127</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 196Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Pro Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr Lys Tyr Ala Ala    50                  55                  60Ala Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser        115                 120                 125</s400><s200><s210>197</s210><s211>336</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 197gagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa gagcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct ggacggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggc                              336</s400><s200><s210>198</s210><s211>381</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 198gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60ccctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180aagtacgccg cggctgtgaa gggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc a                                              381</s400><s200><s210>199</s210><s211>217</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 199Glu Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln1               5                   10                  15Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile Gly Ala Gly            20                  25                  30Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Arg Ala Pro Lys Leu        35                  40                  45Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe    50                  55                  60Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu65                  70                  75                  80Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Thr Ser                85                  90                  95Leu Asp Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly            100                 105                 110Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu        115                 120                 125Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val Ser Asp Phe    130                 135                 140Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val145                 150                 155                 160Lys Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys                165                 170                 175Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser            180                 185                 190His Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser Thr Val Glu        195                 200                 205Lys Thr Val Ala Pro Ala Glu Cys Ser    210                 215</s400><s200><s210>200</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 200Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Pro Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr Lys Tyr Ala Ala    50                  55                  60Ala Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>201</s210><s211>457</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 201Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Pro Cys Thr Ala Ser Gly Phe Ser Phe Gly Asp His            20                  25                  30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala Thr Thr Lys Tyr Ala Ala    50                  55                  60Ala Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile65                  70                  75                  80Val Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr                85                  90                  95Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly Pro Gly Tyr Gln Tyr Tyr            100                 105                 110Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala        115                 120                 125Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser    130                 135                 140Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe145                 150                 155                 160Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly                165                 170                 175Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu            180                 185                 190Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr        195                 200                 205Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys    210                 215                 220Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro225                 230                 235                 240Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys                245                 250                 255Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val            260                 265                 270Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr        275                 280                 285Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu    290                 295                 300Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His305                 310                 315                 320Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys                325                 330                 335Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln            340                 345                 350Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu        355                 360                 365Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro    370                 375                 380Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn385                 390                 395                 400Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu                405                 410                 415Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val            420                 425                 430Phe Ser Cys Ser Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln        435                 440                 445Lys Ser Leu Ser Leu Ser Pro Gly Lys    450                 455</s400><s200><s210>202</s210><s211>651</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 202gagtctgtgc tgacgcagcc gccctcagtg tctggggccc cagggcagag ggtcaccatc     60tcctgcactg ggatgaactc caacatcggg gcaggttatg atgtatactg gtaccaacaa    120cttccaggaa gagcccccaa actcctcatc tatggtaaca gcaatcggcc ctcaggggtc    180cctgaccgat tctctggctc caggtctggc acctcagcct ccctggccat cactgggctc    240caggctgagg atgaggctga ttattactgc cagtcctatg acaccagcct ggacggttgg    300gctttcggcg gagggaccaa gttgaccgtc ctaggccagc ccaaggctgc cccctcggtc    360actctgttcc caccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc    420gtaagtgact tctacccggg agccgtgaca gtggcctgga aggcagatgg cagccccgtc    480aaggtgggag tggagaccac caaaccctcc aaacaaagca acaacaagta tgcggccagc    540agctacctga gcctgacgcc cgagcagtgg aagtcccaca gaagctacag ctgccgggtc    600acgcatgaag ggagcaccgt ggagaagaca gtggcccctg cagaatgctc t             651</s400><s200><s210>203</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 203gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60ccctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180aagtacgccg cggctgtgaa gggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gatgcatgag   1320gctctgcaca accactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>204</s210><s211>1371</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 204gaggtgcagc tggtggagtc tgggggaggc ttggtacagc cagggcggtc cctgagactc     60ccctgtacag cctctgggtt tagttttggt gatcatgcta tgagctgggt ccgccaggct    120ccagggaagg ggctggagtg ggtaggtttc attagaaaga caacttatgg tgcgacaaca    180aagtacgccg cggctgtgaa gggcagattc accatctcgc gagatgattc taaaagcatt    240gtctatctgc aaatgaacag cctgaaaacc gaggacacag ccgtgtattt ctgtactaga    300gtgcagcttg actatggccc gggataccag tactacggta tggacgtctg gggccaaggg    360accacggtca ccgtctcctc agcctccacc aagggcccat cggtcttccc cctggcaccc    420tcctccaaga gcacctctgg gggcacagca gccctgggct gcctggtcaa ggactacttc    480cccgaaccgg tgacggtgtc gtggaactca ggcgccctga ccagcggcgt gcacaccttc    540ccggctgtcc tacagtcctc aggactctac tccctcagca gcgtggtgac cgtgccctcc    600agcagcttgg gcacccagac ctacatctgc aacgtgaatc acaagcccag caacaccaag    660gtggacaaga aagttgagcc caaatcttgt gacaaaactc acacatgccc accgtgccca    720gcacctgaac tcctgggggg accgtcagtc ttcctcttcc ccccaaaacc caaggacacc    780ctcatgatct cccggacccc tgaggtcaca tgcgtggtgg tggacgtgag ccacgaagac    840cctgaggtca agttcaactg gtacgtggac ggcgtggagg tgcataatgc caagacaaag    900ccgcgggagg agcagtacaa cagcacgtac cgtgtggtca gcgtcctcac cgtcctgcac    960caggactggc tgaatggcaa ggagtacaag tgcaaggtct ccaacaaagc cctcccagcc   1020cccatcgaga aaaccatctc caaagccaaa gggcagcccc gagaaccaca ggtgtacacc   1080ctgcccccat cccgggatga gctgaccaag aaccaggtca gcctgacctg cctggtcaaa   1140ggcttctatc ccagcgacat cgccgtggag tgggagagca atgggcagcc ggagaacaac   1200tacaagacca cgcctcccgt gctggactcc gacggctcct tcttcctcta cagcaagctc   1260accgtggaca agagcaggtg gcagcagggg aacgtcttct catgctccgt gctgcatgag   1320gctctgcact cccactacac acagaagagc ctctccctgt ctccgggtaa a            1371</s400><s200><s210>205</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 205Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala1               5                   10</s400><s200><s210>206</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 206Asp Ala Ser Ser Leu Glu Ser1               5</s400><s200><s210>207</s210><s211>10</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 207Gln Gln Tyr Asn Ser Tyr Ser Phe Trp Thr1               5                   10</s400><s200><s210>208</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 208Thr Tyr Gly Met His1               5</s400><s200><s210>209</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 209Ile Ile Trp Tyr Asp Gly Ser Gln Lys Tyr Tyr Ala Asp Ser Val Gln1               5                   10                  15Gly</s400><s200><s210>210</s210><s211>14</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 210Val Arg Phe Ser Val Gly Pro His Gly Ser Ala Phe Asp Leu1               5                   10</s400><s200><s210>211</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 211Arg Ala Ser Gln Ser Ile Ser Ser Trp Leu Ala1               5                   10</s400><s200><s210>212</s210><s211>7</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 212Asp Ala Ser Ser Leu Glu Ser1               5</s400><s200><s210>213</s210><s211>11</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 213Gln Gln Tyr Asn Ser Tyr Ser Phe Trp Thr Phe1               5                   10</s400><s200><s210>214</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 214Thr Tyr Gly Met His1               5</s400><s200><s210>215</s210><s211>17</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 215Ile Ile Trp Tyr Asp Gly Ser Gln Lys Tyr Tyr Ala Asp Ser Val Gln1               5                   10                  15Gly</s400><s200><s210>216</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 216Ser Ala Phe Asp Leu1               5</s400><s200><s210>217</s210><s211>109</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 217Gly Val Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Phe                85                  90                  95Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg            100                 105</s400><s200><s210>218</s210><s211>123</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 218Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Asn Thr Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Ile Ile Trp Tyr Asp Gly Ser Gln Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Gln Gly Arg Phe Ile Ile Ser Arg Asp Asn His Lys Asn Thr Leu Ser65                  70                  75                  80Leu Gln Met Asn Gly Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Val Arg Val Arg Phe Ser Val Gly Pro His Gly Ser Ala Phe Asp Leu            100                 105                 110Trp Gly Gln Gly Thr Met Val Ile Val Ser Ser        115                 120</s400><s200><s210>219</s210><s211>327</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 219ggcgtccaga tgacccagtc tccttccacc ctgtctgcat ctgtgggaga cagagtcacc     60ctcacttgcc gggccagtca gagtattagt agttggttgg cctggtatca gcagaaacca    120gggaaagccc ctaaactcct gatctatgat gcctccagtt tggaaagtgg ggtcccatca    180aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcaacct    240gatgattttg caacttatta ctgccaacag tataatagtt attctttttg gacgttcggc    300caagggacca aggtggaaat caaacgc                                        327</s400><s200><s210>220</s210><s211>369</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 220caggtgcaac tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60tcctgtgcag cgtctgggtt cgctttcaat acctatggca tgcactgggt ccgccagact    120ccaggcaagg ggctggagtg ggtggcaatt atctggtatg atgggagcca gaaatactat    180gcagactccg tgcagggccg attcatcatc tccagagaca atcacaagaa cacgttgtct    240ctgcaaatga acggcctgag agccgaggac acggctgtgt atttctgtgt gagagtccgc    300tttagcgttg gcccccacgg gagtgctttt gatctctggg gccaggggac aatggtcatc    360gtctcttca                                                            369</s400><s200><s210>221</s210><s211>215</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 221Gly Val Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Phe                85                  90                  95Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala            100                 105                 110Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser        115                 120                 125Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu    130                 135                 140Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser145                 150                 155                 160Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu                165                 170                 175Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val            180                 185                 190Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys        195                 200                 205Ser Phe Asn Arg Gly Glu Cys    210                 215</s400><s200><s210>222</s210><s211>453</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 222Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Asn Thr Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Ile Ile Trp Tyr Asp Gly Ser Gln Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Gln Gly Arg Phe Ile Ile Ser Arg Asp Asn His Lys Asn Thr Leu Ser65                  70                  75                  80Leu Gln Met Asn Gly Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Val Arg Val Arg Phe Ser Val Gly Pro His Gly Ser Ala Phe Asp Leu            100                 105                 110Trp Gly Gln Gly Thr Met Val Ile Val Ser Ser Ala Ser Thr Lys Gly        115                 120                 125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly    130                 135                 140Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val145                 150                 155                 160Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe                165                 170                 175Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val            180                 185                 190Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val        195                 200                 205Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys    210                 215                 220Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu225                 230                 235                 240Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr                245                 250                 255Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val            260                 265                 270Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val        275                 280                 285Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser    290                 295                 300Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu305                 310                 315                 320Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala                325                 330                 335Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro            340                 345                 350Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln        355                 360                 365Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala    370                 375                 380Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr385                 390                 395                 400Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu                405                 410                 415Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser            420                 425                 430Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser        435                 440                 445Leu Ser Pro Gly Lys    450</s400><s200><s210>223</s210><s211>453</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 223Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Asn Thr Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Thr Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Ile Ile Trp Tyr Asp Gly Ser Gln Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Gln Gly Arg Phe Ile Ile Ser Arg Asp Asn His Lys Asn Thr Leu Ser65                  70                  75                  80Leu Gln Met Asn Gly Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Val Arg Val Arg Phe Ser Val Gly Pro His Gly Ser Ala Phe Asp Leu            100                 105                 110Trp Gly Gln Gly Thr Met Val Ile Val Ser Ser Ala Ser Thr Lys Gly        115                 120                 125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly    130                 135                 140Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val145                 150                 155                 160Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe                165                 170                 175Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val            180                 185                 190Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val        195                 200                 205Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys    210                 215                 220Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu225                 230                 235                 240Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr                245                 250                 255Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val            260                 265                 270Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val        275                 280                 285Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser    290                 295                 300Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu305                 310                 315                 320Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala                325                 330                 335Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro            340                 345                 350Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln        355                 360                 365Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala    370                 375                 380Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr385                 390                 395                 400Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu                405                 410                 415Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser            420                 425                 430Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln Lys Ser Leu Ser        435                 440                 445Leu Ser Pro Gly Lys    450</s400><s200><s210>224</s210><s211>645</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 224ggcgtccaga tgacccagtc tccttccacc ctgtctgcat ctgtgggaga cagagtcacc     60ctcacttgcc gggccagtca gagtattagt agttggttgg cctggtatca gcagaaacca    120gggaaagccc ctaaactcct gatctatgat gcctccagtt tggaaagtgg ggtcccatca    180aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcaacct    240gatgattttg caacttatta ctgccaacag tataatagtt attctttttg gacgttcggc    300caagggacca aggtggaaat caaacgcact gtggctgcac catctgtctt catcttcccg    360ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc    420tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc    480caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg    540acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag    600ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgt                    645</s400><s200><s210>225</s210><s211>1359</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 225caggtgcaac tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60tcctgtgcag cgtctgggtt cgctttcaat acctatggca tgcactgggt ccgccagact    120ccaggcaagg ggctggagtg ggtggcaatt atctggtatg atgggagcca gaaatactat    180gcagactccg tgcagggccg attcatcatc tccagagaca atcacaagaa cacgttgtct    240ctgcaaatga acggcctgag agccgaggac acggctgtgt atttctgtgt gagagtccgc    300tttagcgttg gcccccacgg gagtgctttt gatctctggg gccaggggac aatggtcatc    360gtctcttcag cctccaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc    420acctctgggg gcacagcagc cctgggctgc ctggtcaagg actacttccc cgaaccggtg    480acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta    540cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc    600acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaaa    660gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaactc    720ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc    780cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag    840ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag    900cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg    960aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa   1020accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc   1080cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc   1140agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg   1200cctcccgtgc tggactccga cggctccttc ttcctctaca gcaagctcac cgtggacaag   1260agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac   1320cactacacac agaagagcct ctccctgtct ccgggtaaa                          1359</s400><s200><s210>226</s210><s211>1359</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 226caggtgcaac tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60tcctgtgcag cgtctgggtt cgctttcaat acctatggca tgcactgggt ccgccagact    120ccaggcaagg ggctggagtg ggtggcaatt atctggtatg atgggagcca gaaatactat    180gcagactccg tgcagggccg attcatcatc tccagagaca atcacaagaa cacgttgtct    240ctgcaaatga acggcctgag agccgaggac acggctgtgt atttctgtgt gagagtccgc    300tttagcgttg gcccccacgg gagtgctttt gatctctggg gccaggggac aatggtcatc    360gtctcttcag cctccaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc    420acctctgggg gcacagcagc cctgggctgc ctggtcaagg actacttccc cgaaccggtg    480acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta    540cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc    600acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaaa    660gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaactc    720ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc    780cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag    840ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag    900cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg    960aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa   1020accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc   1080cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc   1140agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg   1200cctcccgtgc tggactccga cggctccttc ttcctctaca gcaagctcac cgtggacaag   1260agcaggtggc agcaggggaa cgtcttctca tgctccgtgc tgcatgaggc tctgcactcc   1320cactacacac agaagagcct ctccctgtct ccgggtaaa                          1359</s400><s200><s210>227</s210><s211>109</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 227Gly Val Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Phe                85                  90                  95Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg            100                 105</s400><s200><s210>228</s210><s211>123</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 228Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Asn Thr Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Ile Ile Trp Tyr Asp Gly Ser Gln Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Gln Gly Arg Phe Ile Ile Ser Arg Asp Asn His Lys Asn Thr Leu Ser65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Val Arg Val Arg Phe Ser Val Gly Pro His Gly Ser Ala Phe Asp Leu            100                 105                 110Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser        115                 120</s400><s200><s210>229</s210><s211>327</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 229ggcgtccaga tgacccagtc tccttccacc ctgtctgcat ctgtgggaga cagagtcacc     60ctcacttgcc gggccagtca gagtattagt agttggttgg cctggtatca gcagaaacca    120gggaaagccc ctaaactcct gatctatgat gcctccagtt tggaaagtgg ggtcccatca    180aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcaacct    240gatgattttg caacttatta ctgccaacag tataatagtt attctttttg gacgttcggc    300caagggacca aggtggaaat caaacgc                                        327</s400><s200><s210>230</s210><s211>369</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 230caggtgcaac tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60tcctgtgcag cgtctgggtt cgctttcaat acctatggca tgcactgggt ccgccaggca    120ccaggcaagg ggctggagtg ggtggcaatt atctggtatg atgggagcca gaaatactat    180gcagactccg tgcagggccg attcatcatc tccagagaca atcacaagaa cacgttgtct    240ctgcaaatga actccctgag agccgaggac acggctgtgt atttctgtgt gagagtccgc    300tttagcgttg gcccccacgg gagtgctttt gatctctggg gccaggggac aatggtcaca    360gtctcttca                                                            369</s400><s200><s210>231</s210><s211>215</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 231Gly Val Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Phe                85                  90                  95Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala            100                 105                 110Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser        115                 120                 125Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu    130                 135                 140Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser145                 150                 155                 160Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu                165                 170                 175Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val            180                 185                 190Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys        195                 200                 205Ser Phe Asn Arg Gly Glu Cys    210                 215</s400><s200><s210>232</s210><s211>453</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 232Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Asn Thr Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Ile Ile Trp Tyr Asp Gly Ser Gln Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Gln Gly Arg Phe Ile Ile Ser Arg Asp Asn His Lys Asn Thr Leu Ser65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Val Arg Val Arg Phe Ser Val Gly Pro His Gly Ser Ala Phe Asp Leu            100                 105                 110Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly        115                 120                 125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly    130                 135                 140Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val145                 150                 155                 160Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe                165                 170                 175Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val            180                 185                 190Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val        195                 200                 205Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys    210                 215                 220Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu225                 230                 235                 240Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr                245                 250                 255Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val            260                 265                 270Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val        275                 280                 285Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser    290                 295                 300Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu305                 310                 315                 320Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala                325                 330                 335Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro            340                 345                 350Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln        355                 360                 365Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala    370                 375                 380Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr385                 390                 395                 400Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu                405                 410                 415Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser            420                 425                 430Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser        435                 440                 445Leu Ser Pro Gly Lys    450</s400><s200><s210>233</s210><s211>453</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 233Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Asn Thr Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Ile Ile Trp Tyr Asp Gly Ser Gln Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Gln Gly Arg Phe Ile Ile Ser Arg Asp Asn His Lys Asn Thr Leu Ser65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Val Arg Val Arg Phe Ser Val Gly Pro His Gly Ser Ala Phe Asp Leu            100                 105                 110Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly        115                 120                 125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly    130                 135                 140Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val145                 150                 155                 160Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe                165                 170                 175Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val            180                 185                 190Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val        195                 200                 205Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys    210                 215                 220Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu225                 230                 235                 240Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr                245                 250                 255Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val            260                 265                 270Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val        275                 280                 285Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser    290                 295                 300Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu305                 310                 315                 320Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala                325                 330                 335Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro            340                 345                 350Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln        355                 360                 365Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala    370                 375                 380Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr385                 390                 395                 400Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu                405                 410                 415Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser            420                 425                 430Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln Lys Ser Leu Ser        435                 440                 445Leu Ser Pro Gly Lys    450</s400><s200><s210>234</s210><s211>645</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 234ggcgtccaga tgacccagtc tccttccacc ctgtctgcat ctgtgggaga cagagtcacc     60ctcacttgcc gggccagtca gagtattagt agttggttgg cctggtatca gcagaaacca    120gggaaagccc ctaaactcct gatctatgat gcctccagtt tggaaagtgg ggtcccatca    180aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcaacct    240gatgattttg caacttatta ctgccaacag tataatagtt attctttttg gacgttcggc    300caagggacca aggtggaaat caaacgcact gtggctgcac catctgtctt catcttcccg    360ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc    420tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc    480caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg    540acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag    600ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgt                    645</s400><s200><s210>235</s210><s211>1359</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 235caggtgcaac tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60tcctgtgcag cgtctgggtt cgctttcaat acctatggca tgcactgggt ccgccaggca    120ccaggcaagg ggctggagtg ggtggcaatt atctggtatg atgggagcca gaaatactat    180gcagactccg tgcagggccg attcatcatc tccagagaca atcacaagaa cacgttgtct    240ctgcaaatga actccctgag agccgaggac acggctgtgt atttctgtgt gagagtccgc    300tttagcgttg gcccccacgg gagtgctttt gatctctggg gccaggggac aatggtcaca    360gtctcttcag cctccaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc    420acctctgggg gcacagcagc cctgggctgc ctggtcaagg actacttccc cgaaccggtg    480acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta    540cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc    600acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaaa    660gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaactc    720ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc    780cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag    840ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag    900cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg    960aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa   1020accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc   1080cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc   1140agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg   1200cctcccgtgc tggactccga cggctccttc ttcctctaca gcaagctcac cgtggacaag   1260agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac   1320cactacacac agaagagcct ctccctgtct ccgggtaaa                          1359</s400><s200><s210>236</s210><s211>1359</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 236caggtgcaac tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60tcctgtgcag cgtctgggtt cgctttcaat acctatggca tgcactgggt ccgccaggca    120ccaggcaagg ggctggagtg ggtggcaatt atctggtatg atgggagcca gaaatactat    180gcagactccg tgcagggccg attcatcatc tccagagaca atcacaagaa cacgttgtct    240ctgcaaatga actccctgag agccgaggac acggctgtgt atttctgtgt gagagtccgc    300tttagcgttg gcccccacgg gagtgctttt gatctctggg gccaggggac aatggtcaca    360gtctcttcag cctccaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc    420acctctgggg gcacagcagc cctgggctgc ctggtcaagg actacttccc cgaaccggtg    480acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta    540cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc    600acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaaa    660gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaactc    720ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc    780cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag    840ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag    900cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg    960aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa   1020accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc   1080cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc   1140agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg   1200cctcccgtgc tggactccga cggctccttc ttcctctaca gcaagctcac cgtggacaag   1260agcaggtggc agcaggggaa cgtcttctca tgctccgtgc tgcatgaggc tctgcactcc   1320cactacacac agaagagcct ctccctgtct ccgggtaaa                          1359</s400><s200><s210>237</s210><s211>109</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 237Gly Val Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Phe                85                  90                  95Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg            100                 105</s400><s200><s210>238</s210><s211>123</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 238Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Ile Ile Trp Tyr Asp Gly Ser Gln Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Gln Gly Arg Phe Ile Ile Ser Arg Asp Asn His Lys Asn Thr Leu Ser65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Val Arg Val Arg Phe Ser Val Gly Pro His Gly Ser Ala Phe Asp Leu            100                 105                 110Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser        115                 120</s400><s200><s210>239</s210><s211>327</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 239ggcgtccaga tgacccagtc tccttccacc ctgtctgcat ctgtgggaga cagagtcacc     60ctcacttgcc gggccagtca gagtattagt agttggttgg cctggtatca gcagaaacca    120gggaaagccc ctaaactcct gatctatgat gcctccagtt tggaaagtgg ggtcccatca    180aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcaacct    240gatgattttg caacttatta ctgccaacag tataatagtt attctttttg gacgttcggc    300caagggacca aggtggaaat caaacgc                                        327</s400><s200><s210>240</s210><s211>369</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 240caggtgcaac tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60tcctgtgcag cgtctgggtt cactttcaat acctatggca tgcactgggt ccgccaggca    120ccaggcaagg ggctggagtg ggtggcaatt atctggtatg atgggagcca gaaatactat    180gcagactccg tgcagggccg attcatcatc tccagagaca atcacaagaa cacgttgtct    240ctgcaaatga actccctgag agccgaggac acggctgtgt atttctgtgt gagagtccgc    300tttagcgttg gcccccacgg gagtgctttt gatctctggg gccaggggac aatggtcaca    360gtctcttca                                                            369</s400><s200><s210>241</s210><s211>215</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 241Gly Val Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Phe                85                  90                  95Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala            100                 105                 110Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser        115                 120                 125Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu    130                 135                 140Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser145                 150                 155                 160Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu                165                 170                 175Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val            180                 185                 190Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys        195                 200                 205Ser Phe Asn Arg Gly Glu Cys    210                 215</s400><s200><s210>242</s210><s211>453</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 242Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Ile Ile Trp Tyr Asp Gly Ser Gln Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Gln Gly Arg Phe Ile Ile Ser Arg Asp Asn His Lys Asn Thr Leu Ser65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Val Arg Val Arg Phe Ser Val Gly Pro His Gly Ser Ala Phe Asp Leu            100                 105                 110Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly        115                 120                 125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly    130                 135                 140Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val145                 150                 155                 160Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe                165                 170                 175Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val            180                 185                 190Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val        195                 200                 205Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys    210                 215                 220Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu225                 230                 235                 240Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr                245                 250                 255Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val            260                 265                 270Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val        275                 280                 285Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser    290                 295                 300Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu305                 310                 315                 320Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala                325                 330                 335Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro            340                 345                 350Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln        355                 360                 365Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala    370                 375                 380Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr385                 390                 395                 400Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu                405                 410                 415Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser            420                 425                 430Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser        435                 440                 445Leu Ser Pro Gly Lys    450</s400><s200><s210>243</s210><s211>453</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 243Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Ile Ile Trp Tyr Asp Gly Ser Gln Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Gln Gly Arg Phe Ile Ile Ser Arg Asp Asn His Lys Asn Thr Leu Ser65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Val Arg Val Arg Phe Ser Val Gly Pro His Gly Ser Ala Phe Asp Leu            100                 105                 110Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly        115                 120                 125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly    130                 135                 140Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val145                 150                 155                 160Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe                165                 170                 175Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val            180                 185                 190Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val        195                 200                 205Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys    210                 215                 220Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu225                 230                 235                 240Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr                245                 250                 255Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val            260                 265                 270Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val        275                 280                 285Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser    290                 295                 300Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu305                 310                 315                 320Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala                325                 330                 335Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro            340                 345                 350Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln        355                 360                 365Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala    370                 375                 380Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr385                 390                 395                 400Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu                405                 410                 415Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser            420                 425                 430Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln Lys Ser Leu Ser        435                 440                 445Leu Ser Pro Gly Lys    450</s400><s200><s210>244</s210><s211>645</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 244ggcgtccaga tgacccagtc tccttccacc ctgtctgcat ctgtgggaga cagagtcacc     60ctcacttgcc gggccagtca gagtattagt agttggttgg cctggtatca gcagaaacca    120gggaaagccc ctaaactcct gatctatgat gcctccagtt tggaaagtgg ggtcccatca    180aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcaacct    240gatgattttg caacttatta ctgccaacag tataatagtt attctttttg gacgttcggc    300caagggacca aggtggaaat caaacgcact gtggctgcac catctgtctt catcttcccg    360ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc    420tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc    480caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg    540acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag    600ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgt                    645</s400><s200><s210>245</s210><s211>1359</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 245caggtgcaac tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60tcctgtgcag cgtctgggtt cactttcaat acctatggca tgcactgggt ccgccaggca    120ccaggcaagg ggctggagtg ggtggcaatt atctggtatg atgggagcca gaaatactat    180gcagactccg tgcagggccg attcatcatc tccagagaca atcacaagaa cacgttgtct    240ctgcaaatga actccctgag agccgaggac acggctgtgt atttctgtgt gagagtccgc    300tttagcgttg gcccccacgg gagtgctttt gatctctggg gccaggggac aatggtcaca    360gtctcttcag cctccaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc    420acctctgggg gcacagcagc cctgggctgc ctggtcaagg actacttccc cgaaccggtg    480acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta    540cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc    600acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaaa    660gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaactc    720ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc    780cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag    840ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag    900cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg    960aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa   1020accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc   1080cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc   1140agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg   1200cctcccgtgc tggactccga cggctccttc ttcctctaca gcaagctcac cgtggacaag   1260agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac   1320cactacacac agaagagcct ctccctgtct ccgggtaaa                          1359</s400><s200><s210>246</s210><s211>1359</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 246caggtgcaac tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60tcctgtgcag cgtctgggtt cactttcaat acctatggca tgcactgggt ccgccaggca    120ccaggcaagg ggctggagtg ggtggcaatt atctggtatg atgggagcca gaaatactat    180gcagactccg tgcagggccg attcatcatc tccagagaca atcacaagaa cacgttgtct    240ctgcaaatga actccctgag agccgaggac acggctgtgt atttctgtgt gagagtccgc    300tttagcgttg gcccccacgg gagtgctttt gatctctggg gccaggggac aatggtcaca    360gtctcttcag cctccaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc    420acctctgggg gcacagcagc cctgggctgc ctggtcaagg actacttccc cgaaccggtg    480acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta    540cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc    600acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaaa    660gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaactc    720ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc    780cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag    840ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag    900cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg    960aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa   1020accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc   1080cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc   1140agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg   1200cctcccgtgc tggactccga cggctccttc ttcctctaca gcaagctcac cgtggacaag   1260agcaggtggc agcaggggaa cgtcttctca tgctccgtgc tgcatgaggc tctgcactcc   1320cactacacac agaagagcct ctccctgtct ccgggtaaa                          1359</s400><s200><s210>247</s210><s211>109</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 247Gly Val Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Phe                85                  90                  95Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg            100                 105</s400><s200><s210>248</s210><s211>123</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 248Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Asn Thr Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Ile Ile Trp Tyr Asp Gly Ser Gln Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn His Lys Asn Thr Leu Ser65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Val Arg Val Arg Phe Ser Val Gly Pro His Gly Ser Ala Phe Asp Leu            100                 105                 110Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser        115                 120</s400><s200><s210>249</s210><s211>327</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 249ggcgtccaga tgacccagtc tccttccacc ctgtctgcat ctgtgggaga cagagtcacc     60ctcacttgcc gggccagtca gagtattagt agttggttgg cctggtatca gcagaaacca    120gggaaagccc ctaaactcct gatctatgat gcctccagtt tggaaagtgg ggtcccatca    180aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcaacct    240gatgattttg caacttatta ctgccaacag tataatagtt attctttttg gacgttcggc    300caagggacca aggtggaaat caaacgc                                        327</s400><s200><s210>250</s210><s211>369</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 250caggtgcaac tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60tcctgtgcag cgtctgggtt cgctttcaat acctatggca tgcactgggt ccgccaggca    120ccaggcaagg ggctggagtg ggtggcaatt atctggtatg atgggagcca gaaatactat    180gcagactccg tgcagggccg attcactatc tccagagaca atcacaagaa cacgttgtct    240ctgcaaatga actccctgag agccgaggac acggctgtgt atttctgtgt gagagtccgc    300tttagcgttg gcccccacgg gagtgctttt gatctctggg gccaggggac aatggtcaca    360gtctcttca                                                            369</s400><s200><s210>251</s210><s211>215</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 251Gly Val Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Phe                85                  90                  95Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala            100                 105                 110Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser        115                 120                 125Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu    130                 135                 140Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser145                 150                 155                 160Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu                165                 170                 175Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val            180                 185                 190Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys        195                 200                 205Ser Phe Asn Arg Gly Glu Cys    210                 215</s400><s200><s210>252</s210><s211>453</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 252Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Asn Thr Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Ile Ile Trp Tyr Asp Gly Ser Gln Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn His Lys Asn Thr Leu Ser65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Val Arg Val Arg Phe Ser Val Gly Pro His Gly Ser Ala Phe Asp Leu            100                 105                 110Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly        115                 120                 125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly    130                 135                 140Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val145                 150                 155                 160Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe                165                 170                 175Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val            180                 185                 190Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val        195                 200                 205Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys    210                 215                 220Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu225                 230                 235                 240Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr                245                 250                 255Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val            260                 265                 270Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val        275                 280                 285Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser    290                 295                 300Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu305                 310                 315                 320Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala                325                 330                 335Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro            340                 345                 350Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln        355                 360                 365Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala    370                 375                 380Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr385                 390                 395                 400Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu                405                 410                 415Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser            420                 425                 430Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser        435                 440                 445Leu Ser Pro Gly Lys    450</s400><s200><s210>253</s210><s211>453</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 253Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Asn Thr Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Ile Ile Trp Tyr Asp Gly Ser Gln Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn His Lys Asn Thr Leu Ser65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Val Arg Val Arg Phe Ser Val Gly Pro His Gly Ser Ala Phe Asp Leu            100                 105                 110Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly        115                 120                 125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly    130                 135                 140Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val145                 150                 155                 160Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe                165                 170                 175Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val            180                 185                 190Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val        195                 200                 205Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys    210                 215                 220Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu225                 230                 235                 240Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr                245                 250                 255Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val            260                 265                 270Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val        275                 280                 285Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser    290                 295                 300Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu305                 310                 315                 320Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala                325                 330                 335Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro            340                 345                 350Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln        355                 360                 365Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala    370                 375                 380Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr385                 390                 395                 400Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu                405                 410                 415Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser            420                 425                 430Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln Lys Ser Leu Ser        435                 440                 445Leu Ser Pro Gly Lys    450</s400><s200><s210>254</s210><s211>645</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 254ggcgtccaga tgacccagtc tccttccacc ctgtctgcat ctgtgggaga cagagtcacc     60ctcacttgcc gggccagtca gagtattagt agttggttgg cctggtatca gcagaaacca    120gggaaagccc ctaaactcct gatctatgat gcctccagtt tggaaagtgg ggtcccatca    180aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcaacct    240gatgattttg caacttatta ctgccaacag tataatagtt attctttttg gacgttcggc    300caagggacca aggtggaaat caaacgcact gtggctgcac catctgtctt catcttcccg    360ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc    420tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc    480caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg    540acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag    600ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgt                    645</s400><s200><s210>255</s210><s211>1359</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 255caggtgcaac tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60tcctgtgcag cgtctgggtt cgctttcaat acctatggca tgcactgggt ccgccaggca    120ccaggcaagg ggctggagtg ggtggcaatt atctggtatg atgggagcca gaaatactat    180gcagactccg tgcagggccg attcactatc tccagagaca atcacaagaa cacgttgtct    240ctgcaaatga actccctgag agccgaggac acggctgtgt atttctgtgt gagagtccgc    300tttagcgttg gcccccacgg gagtgctttt gatctctggg gccaggggac aatggtcaca    360gtctcttcag cctccaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc    420acctctgggg gcacagcagc cctgggctgc ctggtcaagg actacttccc cgaaccggtg    480acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta    540cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc    600acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaaa    660gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaactc    720ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc    780cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag    840ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag    900cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg    960aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa   1020accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc   1080cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc   1140agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg   1200cctcccgtgc tggactccga cggctccttc ttcctctaca gcaagctcac cgtggacaag   1260agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac   1320cactacacac agaagagcct ctccctgtct ccgggtaaa                          1359</s400><s200><s210>256</s210><s211>1359</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 256caggtgcaac tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60tcctgtgcag cgtctgggtt cgctttcaat acctatggca tgcactgggt ccgccaggca    120ccaggcaagg ggctggagtg ggtggcaatt atctggtatg atgggagcca gaaatactat    180gcagactccg tgcagggccg attcactatc tccagagaca atcacaagaa cacgttgtct    240ctgcaaatga actccctgag agccgaggac acggctgtgt atttctgtgt gagagtccgc    300tttagcgttg gcccccacgg gagtgctttt gatctctggg gccaggggac aatggtcaca    360gtctcttcag cctccaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc    420acctctgggg gcacagcagc cctgggctgc ctggtcaagg actacttccc cgaaccggtg    480acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta    540cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc    600acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaaa    660gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaactc    720ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc    780cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag    840ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag    900cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg    960aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa   1020accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc   1080cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc   1140agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg   1200cctcccgtgc tggactccga cggctccttc ttcctctaca gcaagctcac cgtggacaag   1260agcaggtggc agcaggggaa cgtcttctca tgctccgtgc tgcatgaggc tctgcactcc   1320cactacacac agaagagcct ctccctgtct ccgggtaaa                          1359</s400><s200><s210>257</s210><s211>109</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 257Gly Val Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Phe                85                  90                  95Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg            100                 105</s400><s200><s210>258</s210><s211>123</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 258Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Ile Ile Trp Tyr Asp Gly Ser Gln Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn His Lys Asn Thr Leu Ser65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Val Arg Val Arg Phe Ser Val Gly Pro His Gly Ser Ala Phe Asp Leu            100                 105                 110Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser        115                 120</s400><s200><s210>259</s210><s211>327</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 259ggcgtccaga tgacccagtc tccttccacc ctgtctgcat ctgtgggaga cagagtcacc     60ctcacttgcc gggccagtca gagtattagt agttggttgg cctggtatca gcagaaacca    120gggaaagccc ctaaactcct gatctatgat gcctccagtt tggaaagtgg ggtcccatca    180aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcaacct    240gatgattttg caacttatta ctgccaacag tataatagtt attctttttg gacgttcggc    300caagggacca aggtggaaat caaacgc                                        327</s400><s200><s210>260</s210><s211>369</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 260caggtgcaac tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60tcctgtgcag cgtctgggtt cactttcaat acctatggca tgcactgggt ccgccaggca    120ccaggcaagg ggctggagtg ggtggcaatt atctggtatg atgggagcca gaaatactat    180gcagactccg tgcagggccg attcactatc tccagagaca atcacaagaa cacgttgtct    240ctgcaaatga actccctgag agccgaggac acggctgtgt atttctgtgt gagagtccgc    300tttagcgttg gcccccacgg gagtgctttt gatctctggg gccaggggac aatggtcaca    360gtctcttca                                                            369</s400><s200><s210>261</s210><s211>215</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 261Gly Val Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Phe                85                  90                  95Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala            100                 105                 110Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser        115                 120                 125Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu    130                 135                 140Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser145                 150                 155                 160Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu                165                 170                 175Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val            180                 185                 190Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys        195                 200                 205Ser Phe Asn Arg Gly Glu Cys    210                 215</s400><s200><s210>262</s210><s211>453</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 262Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Ile Ile Trp Tyr Asp Gly Ser Gln Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn His Lys Asn Thr Leu Ser65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Val Arg Val Arg Phe Ser Val Gly Pro His Gly Ser Ala Phe Asp Leu            100                 105                 110Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly        115                 120                 125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly    130                 135                 140Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val145                 150                 155                 160Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe                165                 170                 175Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val            180                 185                 190Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val        195                 200                 205Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys    210                 215                 220Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu225                 230                 235                 240Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr                245                 250                 255Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val            260                 265                 270Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val        275                 280                 285Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser    290                 295                 300Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu305                 310                 315                 320Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala                325                 330                 335Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro            340                 345                 350Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln        355                 360                 365Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala    370                 375                 380Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr385                 390                 395                 400Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu                405                 410                 415Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser            420                 425                 430Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser        435                 440                 445Leu Ser Pro Gly Lys    450</s400><s200><s210>263</s210><s211>453</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 263Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Ile Ile Trp Tyr Asp Gly Ser Gln Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn His Lys Asn Thr Leu Ser65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Val Arg Val Arg Phe Ser Val Gly Pro His Gly Ser Ala Phe Asp Leu            100                 105                 110Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly        115                 120                 125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly    130                 135                 140Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val145                 150                 155                 160Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe                165                 170                 175Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val            180                 185                 190Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val        195                 200                 205Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys    210                 215                 220Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu225                 230                 235                 240Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr                245                 250                 255Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val            260                 265                 270Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val        275                 280                 285Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser    290                 295                 300Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu305                 310                 315                 320Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala                325                 330                 335Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro            340                 345                 350Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln        355                 360                 365Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala    370                 375                 380Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr385                 390                 395                 400Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu                405                 410                 415Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser            420                 425                 430Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln Lys Ser Leu Ser        435                 440                 445Leu Ser Pro Gly Lys    450</s400><s200><s210>264</s210><s211>645</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 264ggcgtccaga tgacccagtc tccttccacc ctgtctgcat ctgtgggaga cagagtcacc     60ctcacttgcc gggccagtca gagtattagt agttggttgg cctggtatca gcagaaacca    120gggaaagccc ctaaactcct gatctatgat gcctccagtt tggaaagtgg ggtcccatca    180aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcaacct    240gatgattttg caacttatta ctgccaacag tataatagtt attctttttg gacgttcggc    300caagggacca aggtggaaat caaacgcact gtggctgcac catctgtctt catcttcccg    360ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc    420tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc    480caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg    540acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag    600ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgt                    645</s400><s200><s210>265</s210><s211>1359</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 265caggtgcaac tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60tcctgtgcag cgtctgggtt cactttcaat acctatggca tgcactgggt ccgccaggca    120ccaggcaagg ggctggagtg ggtggcaatt atctggtatg atgggagcca gaaatactat    180gcagactccg tgcagggccg attcactatc tccagagaca atcacaagaa cacgttgtct    240ctgcaaatga actccctgag agccgaggac acggctgtgt atttctgtgt gagagtccgc    300tttagcgttg gcccccacgg gagtgctttt gatctctggg gccaggggac aatggtcaca    360gtctcttcag cctccaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc    420acctctgggg gcacagcagc cctgggctgc ctggtcaagg actacttccc cgaaccggtg    480acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta    540cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc    600acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaaa    660gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaactc    720ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc    780cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag    840ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag    900cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg    960aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa   1020accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc   1080cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc   1140agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg   1200cctcccgtgc tggactccga cggctccttc ttcctctaca gcaagctcac cgtggacaag   1260agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac   1320cactacacac agaagagcct ctccctgtct ccgggtaaa                          1359</s400><s200><s210>266</s210><s211>1359</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 266caggtgcaac tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60tcctgtgcag cgtctgggtt cactttcaat acctatggca tgcactgggt ccgccaggca    120ccaggcaagg ggctggagtg ggtggcaatt atctggtatg atgggagcca gaaatactat    180gcagactccg tgcagggccg attcactatc tccagagaca atcacaagaa cacgttgtct    240ctgcaaatga actccctgag agccgaggac acggctgtgt atttctgtgt gagagtccgc    300tttagcgttg gcccccacgg gagtgctttt gatctctggg gccaggggac aatggtcaca    360gtctcttcag cctccaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc    420acctctgggg gcacagcagc cctgggctgc ctggtcaagg actacttccc cgaaccggtg    480acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta    540cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc    600acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaaa    660gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaactc    720ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc    780cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag    840ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag    900cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg    960aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa   1020accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc   1080cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc   1140agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg   1200cctcccgtgc tggactccga cggctccttc ttcctctaca gcaagctcac cgtggacaag   1260agcaggtggc agcaggggaa cgtcttctca tgctccgtgc tgcatgaggc tctgcactcc   1320cactacacac agaagagcct ctccctgtct ccgggtaaa                          1359</s400><s200><s210>267</s210><s211>109</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 267Gly Val Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Phe                85                  90                  95Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg            100                 105</s400><s200><s210>268</s210><s211>123</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 268Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Ile Ile Trp Tyr Asp Gly Ser Gln Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn His Lys Asn Thr Leu Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Val Arg Val Arg Phe Ser Val Gly Pro His Gly Ser Ala Phe Asp Leu            100                 105                 110Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser        115                 120</s400><s200><s210>269</s210><s211>327</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 269ggcgtccaga tgacccagtc tccttccacc ctgtctgcat ctgtgggaga cagagtcacc     60ctcacttgcc gggccagtca gagtattagt agttggttgg cctggtatca gcagaaacca    120gggaaagccc ctaaactcct gatctatgat gcctccagtt tggaaagtgg ggtcccatca    180aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcaacct    240gatgattttg caacttatta ctgccaacag tataatagtt attctttttg gacgttcggc    300caagggacca aggtggaaat caaacgc                                        327</s400><s200><s210>270</s210><s211>369</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 270caggtgcaac tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60tcctgtgcag cgtctgggtt cactttcaat acctatggca tgcactgggt ccgccaggca    120ccaggcaagg ggctggagtg ggtggcaatt atctggtatg atgggagcca gaaatactat    180gcagactccg tgcagggccg attcactatc tccagagaca atcacaagaa cacgttgtac    240ctgcaaatga actccctgag agccgaggac acggctgtgt atttctgtgt gagagtccgc    300tttagcgttg gcccccacgg gagtgctttt gatctctggg gccaggggac aatggtcaca    360gtctcttca                                                            369</s400><s200><s210>271</s210><s211>215</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 271Gly Val Gln Met Thr Gln Ser Pro Ser Thr Leu Ser Ala Ser Val Gly1               5                   10                  15Asp Arg Val Thr Leu Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Trp            20                  25                  30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile        35                  40                  45Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly    50                  55                  60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65                  70                  75                  80Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Ser Phe                85                  90                  95Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala            100                 105                 110Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser        115                 120                 125Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu    130                 135                 140Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser145                 150                 155                 160Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu                165                 170                 175Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val            180                 185                 190Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys        195                 200                 205Ser Phe Asn Arg Gly Glu Cys    210                 215</s400><s200><s210>272</s210><s211>453</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 272Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Ile Ile Trp Tyr Asp Gly Ser Gln Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn His Lys Asn Thr Leu Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Val Arg Val Arg Phe Ser Val Gly Pro His Gly Ser Ala Phe Asp Leu            100                 105                 110Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly        115                 120                 125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly    130                 135                 140Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val145                 150                 155                 160Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe                165                 170                 175Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val            180                 185                 190Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val        195                 200                 205Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys    210                 215                 220Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu225                 230                 235                 240Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr                245                 250                 255Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val            260                 265                 270Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val        275                 280                 285Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser    290                 295                 300Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu305                 310                 315                 320Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala                325                 330                 335Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro            340                 345                 350Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln        355                 360                 365Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala    370                 375                 380Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr385                 390                 395                 400Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu                405                 410                 415Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser            420                 425                 430Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser        435                 440                 445Leu Ser Pro Gly Lys    450</s400><s200><s210>273</s210><s211>453</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 273Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1               5                   10                  15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asn Thr Tyr            20                  25                  30Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val        35                  40                  45Ala Ile Ile Trp Tyr Asp Gly Ser Gln Lys Tyr Tyr Ala Asp Ser Val    50                  55                  60Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn His Lys Asn Thr Leu Tyr65                  70                  75                  80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys                85                  90                  95Val Arg Val Arg Phe Ser Val Gly Pro His Gly Ser Ala Phe Asp Leu            100                 105                 110Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly        115                 120                 125Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly    130                 135                 140Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val145                 150                 155                 160Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe                165                 170                 175Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val            180                 185                 190Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val        195                 200                 205Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys    210                 215                 220Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu225                 230                 235                 240Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr                245                 250                 255Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val            260                 265                 270Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val        275                 280                 285Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser    290                 295                 300Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu305                 310                 315                 320Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala                325                 330                 335Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro            340                 345                 350Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln        355                 360                 365Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala    370                 375                 380Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr385                 390                 395                 400Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu                405                 410                 415Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser            420                 425                 430Val Leu His Glu Ala Leu His Ser His Tyr Thr Gln Lys Ser Leu Ser        435                 440                 445Leu Ser Pro Gly Lys    450</s400><s200><s210>274</s210><s211>645</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 274ggcgtccaga tgacccagtc tccttccacc ctgtctgcat ctgtgggaga cagagtcacc     60ctcacttgcc gggccagtca gagtattagt agttggttgg cctggtatca gcagaaacca    120gggaaagccc ctaaactcct gatctatgat gcctccagtt tggaaagtgg ggtcccatca    180aggttcagcg gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcaacct    240gatgattttg caacttatta ctgccaacag tataatagtt attctttttg gacgttcggc    300caagggacca aggtggaaat caaacgcact gtggctgcac catctgtctt catcttcccg    360ccatctgatg agcagttgaa atctggaact gcctctgttg tgtgcctgct gaataacttc    420tatcccagag aggccaaagt acagtggaag gtggataacg ccctccaatc gggtaactcc    480caggagagtg tcacagagca ggacagcaag gacagcacct acagcctcag cagcaccctg    540acgctgagca aagcagacta cgagaaacac aaagtctacg cctgcgaagt cacccatcag    600ggcctgagct cgcccgtcac aaagagcttc aacaggggag agtgt                    645</s400><s200><s210>275</s210><s211>1359</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 275caggtgcaac tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60tcctgtgcag cgtctgggtt cactttcaat acctatggca tgcactgggt ccgccaggca    120ccaggcaagg ggctggagtg ggtggcaatt atctggtatg atgggagcca gaaatactat    180gcagactccg tgcagggccg attcactatc tccagagaca atcacaagaa cacgttgtac    240ctgcaaatga actccctgag agccgaggac acggctgtgt atttctgtgt gagagtccgc    300tttagcgttg gcccccacgg gagtgctttt gatctctggg gccaggggac aatggtcaca    360gtctcttcag cctccaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc    420acctctgggg gcacagcagc cctgggctgc ctggtcaagg actacttccc cgaaccggtg    480acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta    540cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc    600acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaaa    660gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaactc    720ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc    780cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag    840ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag    900cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg    960aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa   1020accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc   1080cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc   1140agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg   1200cctcccgtgc tggactccga cggctccttc ttcctctaca gcaagctcac cgtggacaag   1260agcaggtggc agcaggggaa cgtcttctca tgctccgtga tgcatgaggc tctgcacaac   1320cactacacac agaagagcct ctccctgtct ccgggtaaa                          1359</s400><s200><s210>276</s210><s211>1359</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 276caggtgcaac tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc     60tcctgtgcag cgtctgggtt cactttcaat acctatggca tgcactgggt ccgccaggca    120ccaggcaagg ggctggagtg ggtggcaatt atctggtatg atgggagcca gaaatactat    180gcagactccg tgcagggccg attcactatc tccagagaca atcacaagaa cacgttgtac    240ctgcaaatga actccctgag agccgaggac acggctgtgt atttctgtgt gagagtccgc    300tttagcgttg gcccccacgg gagtgctttt gatctctggg gccaggggac aatggtcaca    360gtctcttcag cctccaccaa gggcccatcg gtcttccccc tggcaccctc ctccaagagc    420acctctgggg gcacagcagc cctgggctgc ctggtcaagg actacttccc cgaaccggtg    480acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta    540cagtcctcag gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc    600acccagacct acatctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaaa    660gttgagccca aatcttgtga caaaactcac acatgcccac cgtgcccagc acctgaactc    720ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc    780cggacccctg aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag    840ttcaactggt acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag    900cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg    960aatggcaagg agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa   1020accatctcca aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc   1080cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc   1140agcgacatcg ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg   1200cctcccgtgc tggactccga cggctccttc ttcctctaca gcaagctcac cgtggacaag   1260agcaggtggc agcaggggaa cgtcttctca tgctccgtgc tgcatgaggc tctgcactcc   1320cactacacac agaagagcct ctccctgtct ccgggtaaa                          1359</s400><s200><s210>277</s210><s211>19</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 277Met Ala Trp Ala Leu Leu Leu Leu Thr Leu Leu Thr Gln Gly Thr Gly1               5                   10                  15Ser Trp Ala</s400><s200><s210>278</s210><s211>22</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 278Met Asp Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Leu Trp1               5                   10                  15Leu Arg Gly Ala Arg Cys            20</s400><s200><s210>279</s210><s211>24</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 279Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro1               5                   10                  15Asn Ala Asn Pro Asn Ala Asn Pro            20</s400><s200><s210>280</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 280Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala1               5                   10</s400><s200><s210>281</s210><s211>20</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 281Asn Val Asp Pro Asn Ala Asn Pro Asn Val Asp Pro Asn Ala Asn Pro1               5                   10                  15Asn Val Asp Pro            20</s400><s200><s210>282</s210><s211>16</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 282Asn Pro Asp Pro Asn Ala Asn Pro Asn Val Asp Pro Asn Ala Asn Pro1               5                   10                  15</s400><s200><s210>283</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 283Asp Pro Asn Ala Asn Pro Asn Val Asp Pro Asn Ala1               5                   10</s400><s200><s210>284</s210><s211>15</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 284Lys Gln Pro Ala Asp Gly Asn Pro Asp Pro Asn Ala Asn Pro Asn1               5                   10                  15</s400><s200><s210>285</s210><s211>424</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 285Met Met Arg Lys Leu Ala Ile Leu Ser Val Ser Ser Phe Leu Phe Val1               5                   10                  15Glu Ala Leu Phe Gln Glu Tyr Gln Cys Tyr Gly Ser Ser Ser Asn Thr            20                  25                  30Arg Val Leu Asn Glu Leu Asn Tyr Asp Asn Ala Gly Ile Asn Leu Tyr        35                  40                  45Asn Glu Leu Glu Met Asn Tyr Tyr Gly Lys Gln Glu Asn Trp Tyr Ser    50                  55                  60Leu Lys Lys Asn Ser Arg Ser Leu Gly Glu Asn Asp Asp Gly Asn Asn65                  70                  75                  80Asn Asn Gly Asp Asn Gly Arg Glu Gly Lys Asp Glu Asp Lys Arg Asp                85                  90                  95Gly Asn Asn Glu Asp Asn Glu Lys Leu Arg Lys Pro Lys His Lys Lys            100                 105                 110Leu Lys Gln Pro Gly Asp Gly Asn Pro Asp Pro Asn Ala Asn Pro Asn        115                 120                 125Val Asp Pro Asn Ala Asn Pro Asn Val Asp Pro Asn Ala Asn Pro Asn    130                 135                 140Val Asp Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn145                 150                 155                 160Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn                165                 170                 175Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn            180                 185                 190Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn        195                 200                 205Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn    210                 215                 220Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn225                 230                 235                 240Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn                245                 250                 255Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn            260                 265                 270Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn        275                 280                 285Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro Asn Lys Asn Asn Gln    290                 295                 300Gly Asn Gly Gln Gly His Asn Met Pro Asn Asp Pro Asn Arg Asn Val305                 310                 315                 320Asp Glu Asn Ala Asn Ala Asn Asn Ala Val Lys Asn Asn Asn Asn Glu                325                 330                 335Glu Pro Ser Asp Lys His Ile Glu Gln Tyr Leu Lys Lys Ile Gln Asn            340                 345                 350Ser Leu Ser Thr Glu Trp Ser Pro Cys Ser Val Thr Cys Gly Asn Gly        355                 360                 365Ile Gln Val Arg Ile Lys Pro Gly Ser Ala Asn Lys Pro Lys Asp Glu    370                 375                 380Leu Asp Tyr Glu Asn Asp Ile Glu Lys Lys Ile Cys Lys Met Glu Lys385                 390                 395                 400Cys Ser Ser Val Phe Asn Val Val Asn Ser Ser Ile Gly Leu Ile Met                405                 410                 415Val Leu Ser Phe Leu Phe Leu Asn            420</s400><s200><s210>286</s210><s211>236</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 286Met Ala Trp Ala Leu Leu Leu Leu Thr Leu Leu Thr Gln Gly Thr Gly1               5                   10                  15Ser Trp Ala Glu Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala            20                  25                  30Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Met Asn Ser Asn Ile        35                  40                  45Gly Ala Gly Tyr Asp Val Tyr Trp Tyr Gln Gln Leu Pro Gly Arg Ala    50                  55                  60Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val Pro65                  70                  75                  80Asp Arg Phe Ser Gly Ser Arg Ser Gly Thr Ser Ala Ser Leu Ala Ile                85                  90                  95Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr            100                 105                 110Asp Thr Ser Leu Asn Gly Trp Ala Phe Gly Gly Gly Thr Lys Leu Thr        115                 120                 125Val Leu Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro    130                 135                 140Ser Ser Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val145                 150                 155                 160Ser Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly                165                 170                 175Ser Pro Val Lys Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser            180                 185                 190Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln        195                 200                 205Trp Lys Ser His Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser    210                 215                 220Thr Val Glu Lys Thr Val Ala Pro Ala Glu Cys Ser225                 230                 235</s400><s200><s210>287</s210><s211>479</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 287Met Asp Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Leu Trp1               5                   10                  15Leu Arg Gly Ala Arg Cys Glu Val Gln Leu Val Glu Ser Gly Gly Gly            20                  25                  30Leu Val Gln Pro Gly Arg Ser Leu Arg Leu Pro Cys Thr Ala Ser Gly        35                  40                  45Phe Ser Phe Gly Asp His Ala Met Ser Trp Val Arg Gln Ala Pro Gly    50                  55                  60Lys Gly Leu Glu Trp Val Gly Phe Ile Arg Lys Thr Thr Tyr Gly Ala65                  70                  75                  80Thr Thr His Tyr Ala Ala Ala Val Arg Gly Arg Phe Thr Ile Ser Arg                85                  90                  95Asp Asp Ser Lys Ser Ile Val Tyr Leu Gln Met Asn Ser Leu Lys Thr            100                 105                 110Glu Asp Thr Ala Val Tyr Phe Cys Thr Arg Val Gln Leu Asp Tyr Gly        115                 120                 125Pro Gly Tyr Gln Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr    130                 135                 140Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu145                 150                 155                 160Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys                165                 170                 175Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser            180                 185                 190Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser        195                 200                 205Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser    210                 215                 220Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn225                 230                 235                 240Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His                245                 250                 255Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val            260                 265                 270Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr        275                 280                 285Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu    290                 295                 300Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys305                 310                 315                 320Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser                325                 330                 335Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys            340                 345                 350Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile        355                 360                 365Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro    370                 375                 380Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu385                 390                 395                 400Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn                405                 410                 415Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser            420                 425                 430Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg        435                 440                 445Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Leu His Glu Ala Leu    450                 455                 460His Ser His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys465                 470                 475</s400><s200><s210>288</s210><s211>237</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 288Met Asp Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Leu Trp1               5                   10                  15Leu Arg Gly Ala Arg Cys Gly Val Gln Met Thr Gln Ser Pro Ser Thr            20                  25                  30Leu Ser Ala Ser Val Gly Asp Arg Val Thr Leu Thr Cys Arg Ala Ser        35                  40                  45Gln Ser Ile Ser Ser Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys    50                  55                  60Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Ser Leu Glu Ser Gly Val65                  70                  75                  80Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr                85                  90                  95Ile Ser Ser Leu Gln Pro Asp Asp Phe Ala Thr Tyr Tyr Cys Gln Gln            100                 105                 110Tyr Asn Ser Tyr Ser Phe Trp Thr Phe Gly Gln Gly Thr Lys Val Glu        115                 120                 125Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser    130                 135                 140Asp Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn145                 150                 155                 160Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala                165                 170                 175Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys            180                 185                 190Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp        195                 200                 205Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu    210                 215                 220Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys225                 230                 235</s400><s200><s210>289</s210><s211>475</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Synthetic</s223></s220></s200><s400> 289Met Asp Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Leu Trp1               5                   10                  15Leu Arg Gly Ala Arg Cys Gln Val Gln Leu Val Glu Ser Gly Gly Gly            20                  25                  30Val Val Gln Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly        35                  40                  45Phe Ala Phe Asn Thr Tyr Gly Met His Trp Val Arg Gln Thr Pro Gly    50                  55                  60Lys Gly Leu Glu Trp Val Ala Ile Ile Trp Tyr Asp Gly Ser Gln Lys65                  70                  75                  80Tyr Tyr Ala Asp Ser Val Gln Gly Arg Phe Ile Ile Ser Arg Asp Asn                85                  90                  95His Lys Asn Thr Leu Ser Leu Gln Met Asn Gly Leu Arg Ala Glu Asp            100                 105                 110Thr Ala Val Tyr Phe Cys Val Arg Val Arg Phe Ser Val Gly Pro His        115                 120                 125Gly Ser Ala Phe Asp Leu Trp Gly Gln Gly Thr Met Val Ile Val Ser    130                 135                 140Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser145                 150                 155                 160Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp                165                 170                 175Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr            180                 185                 190Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr        195                 200                 205Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln    210                 215                 220Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp225                 230                 235                 240Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro                245                 250                 255Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro            260                 265                 270Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr        275                 280                 285Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn    290                 295                 300Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg305                 310                 315                 320Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val                325                 330                 335Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser            340                 345                 350Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys        355                 360                 365Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp    370                 375                 380Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe385                 390                 395                 400Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu                405                 410                 415Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe            420                 425                 430Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly        435                 440                 445Asn Val Phe Ser Cys Ser Val Leu His Glu Ala Leu His Ser His Tyr    450                 455                 460Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys465                 470                 475</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230002484A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230002484</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17929824</doc-number><date>20220906</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><priority-claims><priority-claim sequence="01" kind="national"><country>SG</country><doc-number>10202102086S</doc-number><date>20210301</date></priority-claim><priority-claim sequence="02" kind="national"><country>SG</country><doc-number>10202110688T</doc-number><date>20210927</date></priority-claim></priority-claims><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>24</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>244</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>2039</main-group><subgroup>545</subgroup><symbol-position>L</symbol-position><classification-value>A</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e79">TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF</invention-title><us-related-documents><continuation-in-part><relation><parent-doc><document-id><country>US</country><doc-number>PCT/SG2022/050102</doc-number><date>20220301</date></document-id><parent-status>PENDING</parent-status></parent-doc><child-doc><document-id><country>US</country><doc-number>17929824</doc-number></document-id></child-doc></relation></continuation-in-part></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="obligated-assignee"><addressbook><orgname>Aslan Pharmaceuticals PTE LTD</orgname><address><city>Singapore</city><country>SG</country></address></addressbook><residence><country>SG</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>VEVERKA</last-name><first-name>Karen</first-name><address><city>Singapore</city><country>SG</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>WARD</last-name><first-name>Alison</first-name><address><city>Singapore</city><country>SG</country></address></addressbook></inventor></inventors></us-parties></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">An antibody, antigen binding fragment thereof or a pharmaceutical formulation, which is an inhibitor of signalling through IL-13R&#x3b1;1 by binding said receptor and compositions comprising the same for use in the treatment of atopic dermatitis (for example moderate to severe atopic dermatitis, in particular poorly controlled moderate to severe atopic dermatitis) by parenteral administration of a treatment cycle comprising a dose in the range 200 mg to 600 mg, (such as 400 to 600 mg), wherein the disease is modified by a percentage reduction in EASI score in the range &#x2212;20 to &#x2212;100% from the baseline.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="91.36mm" wi="151.72mm" file="US20230002484A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="243.25mm" wi="149.01mm" orientation="landscape" file="US20230002484A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="226.82mm" wi="133.86mm" orientation="landscape" file="US20230002484A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="242.74mm" wi="129.54mm" orientation="landscape" file="US20230002484A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="189.57mm" wi="169.33mm" file="US20230002484A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="137.33mm" wi="145.03mm" file="US20230002484A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="205.99mm" wi="166.88mm" file="US20230002484A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="221.66mm" wi="158.33mm" orientation="landscape" file="US20230002484A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="248.33mm" wi="158.92mm" orientation="landscape" file="US20230002484A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00009" num="00009"><img id="EMI-D00009" he="250.02mm" wi="158.24mm" orientation="landscape" file="US20230002484A1-20230105-D00009.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00010" num="00010"><img id="EMI-D00010" he="232.83mm" wi="158.50mm" orientation="landscape" file="US20230002484A1-20230105-D00010.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00011" num="00011"><img id="EMI-D00011" he="204.64mm" wi="156.46mm" orientation="landscape" file="US20230002484A1-20230105-D00011.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00012" num="00012"><img id="EMI-D00012" he="212.01mm" wi="158.24mm" orientation="landscape" file="US20230002484A1-20230105-D00012.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00013" num="00013"><img id="EMI-D00013" he="84.75mm" wi="158.75mm" file="US20230002484A1-20230105-D00013.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00014" num="00014"><img id="EMI-D00014" he="246.38mm" wi="158.07mm" orientation="landscape" file="US20230002484A1-20230105-D00014.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00015" num="00015"><img id="EMI-D00015" he="243.92mm" wi="158.83mm" orientation="landscape" file="US20230002484A1-20230105-D00015.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00016" num="00016"><img id="EMI-D00016" he="220.47mm" wi="163.15mm" file="US20230002484A1-20230105-D00016.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00017" num="00017"><img id="EMI-D00017" he="234.10mm" wi="158.92mm" file="US20230002484A1-20230105-D00017.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00018" num="00018"><img id="EMI-D00018" he="233.09mm" wi="160.44mm" file="US20230002484A1-20230105-D00018.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00019" num="00019"><img id="EMI-D00019" he="112.95mm" wi="162.39mm" file="US20230002484A1-20230105-D00019.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00020" num="00020"><img id="EMI-D00020" he="233.85mm" wi="158.24mm" orientation="landscape" file="US20230002484A1-20230105-D00020.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00021" num="00021"><img id="EMI-D00021" he="217.51mm" wi="158.67mm" orientation="landscape" file="US20230002484A1-20230105-D00021.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00022" num="00022"><img id="EMI-D00022" he="225.55mm" wi="152.40mm" orientation="landscape" file="US20230002484A1-20230105-D00022.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00023" num="00023"><img id="EMI-D00023" he="129.03mm" wi="165.10mm" file="US20230002484A1-20230105-D00023.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00024" num="00024"><img id="EMI-D00024" he="197.10mm" wi="159.85mm" file="US20230002484A1-20230105-D00024.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00025" num="00025"><img id="EMI-D00025" he="233.60mm" wi="158.41mm" orientation="landscape" file="US20230002484A1-20230105-D00025.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00026" num="00026"><img id="EMI-D00026" he="101.43mm" wi="163.58mm" file="US20230002484A1-20230105-D00026.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00027" num="00027"><img id="EMI-D00027" he="219.63mm" wi="162.39mm" file="US20230002484A1-20230105-D00027.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00028" num="00028"><img id="EMI-D00028" he="239.86mm" wi="139.45mm" orientation="landscape" file="US20230002484A1-20230105-D00028.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00029" num="00029"><img id="EMI-D00029" he="219.20mm" wi="161.37mm" file="US20230002484A1-20230105-D00029.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00030" num="00030"><img id="EMI-D00030" he="216.49mm" wi="162.73mm" file="US20230002484A1-20230105-D00030.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00031" num="00031"><img id="EMI-D00031" he="221.15mm" wi="164.51mm" file="US20230002484A1-20230105-D00031.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00032" num="00032"><img id="EMI-D00032" he="222.17mm" wi="158.67mm" orientation="landscape" file="US20230002484A1-20230105-D00032.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00033" num="00033"><img id="EMI-D00033" he="233.60mm" wi="132.00mm" orientation="landscape" file="US20230002484A1-20230105-D00033.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00034" num="00034"><img id="EMI-D00034" he="233.60mm" wi="167.47mm" file="US20230002484A1-20230105-D00034.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00035" num="00035"><img id="EMI-D00035" he="227.67mm" wi="167.13mm" file="US20230002484A1-20230105-D00035.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00036" num="00036"><img id="EMI-D00036" he="241.22mm" wi="136.91mm" orientation="landscape" file="US20230002484A1-20230105-D00036.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00037" num="00037"><img id="EMI-D00037" he="237.07mm" wi="131.83mm" orientation="landscape" file="US20230002484A1-20230105-D00037.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00038" num="00038"><img id="EMI-D00038" he="172.89mm" wi="146.30mm" file="US20230002484A1-20230105-D00038.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00039" num="00039"><img id="EMI-D00039" he="176.11mm" wi="141.14mm" file="US20230002484A1-20230105-D00039.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0001" level="1">CROSS-REFERENCE TO RELATED APPLICATIONS</heading><p id="p-0002" num="0001">This application is a Continuation-in-Part of International Patent Application No. PCT/SG2022/050102 filed on Mar. 1, 2022, which claims priority to Singapore Application No. SG10202110688T filed on Sep. 27, 2021 and Singapore Application No. SG10202102086S filed on Mar. 1, 2021, the content of each of which applications is incorporated herein by reference.</p><heading id="h-0002" level="1">INCORPORATION OF SEQUENCE LISTING</heading><p id="p-0003" num="0002">This application contains a sequence listing submitted electronically via EFS-web, which serves as both the paper copy and the computer readable form (CRF) and consists of a file entitled &#x201c;STAPL16CIP_seqlistxml&#x201d;, which was created on Sep. 6, 2022, which is 83,245 bytes in size, and which is herein incorporated by reference in its entirety.</p><p id="p-0004" num="0003">The present disclosure relates to use of an anti-IL-13R&#x3b1;1 antibody or a binding fragment thereof and pharmaceutical formulations comprising same to treat patients with atopic dermatitis to stimulate disease modification.</p><heading id="h-0003" level="1">BACKGROUND</heading><p id="p-0005" num="0004">One way to inhibit the activity of IL-13 is to interfere with the binding of IL-13 to its receptor IL-13R, for example by using an antibody specific to IL-13R, such as an antibody specific to IL-13R&#x3b1;1. An effective antibody antagonist to IL-13R&#x3b1;1 may also interfere with the binding of IL-13 and prevent heterodimerization of IL-4R&#x3b1; and IL-13R&#x3b1;1. Such an antibody could inhibit signaling of both IL-13 and IL-4 through the type II receptor while sparing IL-4 signalling through the type I receptor. Signalling through the type I receptor is essential in the induction phase of the immune response during which Th2 cells differentiate. T cells do not express IL-13R&#x3b1;1 so the type II receptor plays no role in Th2 differentiation. Hence, an IL-13R&#x3b1;1 antibody should not affect the overall Th1/Th2 balance. Signalling through the type II IL-4/IL-13 receptor is critical during the effector-A-stage of the immune response during established allergic inflammation. Thus, blockade of the type II receptor should have a beneficial effect on many of the symptoms of conditions mediated by IL-13R-mediated and therefore, be an effective disease modifying agent.</p><p id="p-0006" num="0005">Antibodies against IL-13R&#x3b1;1 (both monoclonal and polyclonal) have been described in the art; see, eg, WO 97/15663, WO 03/80675; WO 03/46009; WO 06/072564; Gauchat et al, 1998 Eur. J. Immunol. 28: 4286-4298; Gauchat et al, 2000 Eur. J. Immunol. 30: 3157-3164; Clement et al, 1997 Cytokine 9(11): 959 (Meeting Abstract); Ogata et al, 1998 J. Biol. Chem. 273: 9864-9871; Graber et al, 1998 Eur. J. Immunol. 28: 4286-4298; C. Vermot-Desroches et al, 2000 Tissue Antigens 5(Supp. 1): 52-53 (Meeting Abstract); Poudrier et al, 2000 Eur. J. Immunol. 30: 3157-3164; Akaiwa et al, 2001 Cytokine 13: 75-84; Cancino-Diaz et al, 2002 J. Invest Dermatol. 119: 1114-1120; and Krause et al, 2006 MoI. Immunol. 43: 1799-1807.</p><p id="p-0007" num="0006">One particularly promising anti-IL-13R&#x3b1;1 antibody is described in WO2008/060813 as antibody 10G5-6. 10G5-6 as an IgG4 with a hinge stabilising serine to proline mutation (S241P Kabat numbering) is known as ASLAN004. ASLAN004 has been shown to bind to human IL-13R&#x3b1;1 with a high affinity (for example Kd may be 500 pM). ASLAN004 was shown to effectively antagonise IL-13 function through inhibiting the binding of IL-13 to its receptor IL-13R&#x3b1;1 and to inhibit IL-13 and IL-4 induced eotaxin release in NHDF cells, IL-13 and IL-4 induced STAT6 phosphorylation in NHDF cells and IL-13 stimulated release of TARC in blood or peripheral blood mononuclear cells. Atopic dermatitis can be a very painful, demoralising and psychologically damaging disease. One method of assessing the disease is the EASI score. The score is in the range 0-72.</p><p id="p-0008" num="0007">In some instances, moderate to severe forms of the disease are not adequately controlled by topical medicines. In addition, it is not advisable for some patients to take the available topical medicines. Dupixent (dupilumab) is an antibody inhibitor of the interleukin-4 receptor alpha (IL-4R&#x3b1;), which is licensed for the treatment of atopic dermatitis.</p><p id="p-0009" num="0000">At phase 2b, at a dose of 300 mg of dupilumab once a week, at day 57, fifty percent of patients had EASI 75 (a 75% reductions from baseline) and thirty percent of patients had an EASI 90 (a 90% percent reduction from baseline).</p><p id="p-0010" num="0008">In contrast it may be that higher levels of disease modification can be achieved in the same or shorter timeframes by targeting IL-13R&#x3b1;1.</p><heading id="h-0004" level="1">SUMMARY OF THE DISCLOSURE</heading><p id="p-0011" num="0009">1. An antibody, antigen binding fragment thereof or a pharmaceutical formulation comprising same, which is an inhibitor of signalling through IL-13R&#x3b1;1 by binding the said receptor, for use in the treatment of atopic dermatitis (for example moderate to severe atopic dermatitis, in particular poorly controlled moderate to severe atopic dermatitis) by parenteral administration of a treatment cycle comprising a dose in the range 200 mg to 600 mg, (such as 400 to 600 mg), wherein the disease is modified by a percentage reduction in EASI score in the range &#x2212;20 to &#x2212;100% from the baseline.<br/>1A. An antibody, antigen binding fragment thereof or a pharmaceutical formulation, which is an inhibitor of signalling through IL-13R&#x3b1;1 by binding the said receptor, for use in the treatment to reduce EASI score in the range &#x2212;20 to &#x2212;100% from the baseline in a patient with atopic dermatitis, for example moderate to severe atopic dermatitis (in particular poorly controlled moderate to severe atopic dermatitis) by parenteral administration of a treatment cycle comprising a dose in the range 200 mg to 600 mg, (such as 400 to 600 mg).<br/>2. An antibody, antigen binding fragment thereof or a pharmaceutical formulation according to paragraph 1 or 1A, wherein reduction in EASI score is present after about two weeks from administration of the first dose (such as day 15).<br/>3. An antibody, antigen binding fragment thereof or a pharmaceutical formulation according to paragraph 1, 1A or 2, wherein reduction in EASI score is present after about four weeks from administration of the first dose (such as day 29).<br/>4. An antibody, antigen binding fragment thereof or a pharmaceutical formulation according to any one of paragraphs 1, 1A to 3, wherein reduction in EASI score is present after about six weeks from administration of the first dose (such as day 43).<br/>5. An antibody, antigen binding fragment thereof or a pharmaceutical formulation according to any one of paragraphs 1, 1A to 4, wherein reduction in EASI score is present after about eight weeks from administration of the first dose (such as day 57).<br/>6. An antibody, antigen binding fragment thereof or a pharmaceutical formulation according to any one of paragraphs 1, 1A to 5, wherein the treatment is administered intravenously.<br/>7. An antibody, antigen binding fragment thereof or a pharmaceutical formulation according to any one of paragraphs 1, 1A to 5, wherein the treatment is administered subcutaneously.<br/>8. An antibody, antigen binding fragment thereof or a pharmaceutical formulation according to any one of paragraphs 1, 1A to 7, wherein multiple doses are administered in a treatment cycle (for example wherein the treatment cycle is 4 to 8 weeks, such as 8 weeks).<br/>9. An antibody, binding fragment thereof or a pharmaceutical formulation according to paragraph 8, wherein multiple treatment cycles are administered, for example 2, 3, 4 or more treatment cycles are administered.<br/>10. An antibody, binding fragment thereof or a pharmaceutical formulation according to paragraph 8 or 9, wherein following the treatment cycle or cycles and disease modification, maintenance therapy is administered, for example the same dose administered less frequently (for example monthly), or a lower dose (such as 200 mg) administered the same frequency or less frequently (such as about two weekly, about three weekly, or about four weekly.<br/>11. An antibody, antigen binding fragment or a pharmaceutical formulation according to any one of paragraphs 1, 1A to 7, wherein said antibody or binding fragment thereof is administered approximately weekly, (in particular a single treatment cycle, especially 8 weeks).<br/>12. An antibody, antigen binding fragment or a pharmaceutical formulation according to any one of paragraphs 1, 1A to 10, wherein said antibody or binding fragment thereof is administered once approximately every two weeks, (in particular a single treatment cycle, especially 8 weeks).<br/>13. An antibody, antigen binding fragment or a pharmaceutical formulation according to any one of paragraphs 1, 1A to 10, wherein said antibody or binding fragment thereof is administered once approximately every three weeks, (in particular a single treatment cycle, especially 8 weeks).<br/>14. An antibody, antigen binding fragment or a pharmaceutical formulation according to any one of paragraphs 1, 1A to 10, wherein the antibody or binding fragment thereof is administered once approximately every four weeks (for example monthly), (in particular a single treatment cycle, especially 8 weeks).<br/>15. An antibody, antigen binding fragment or a pharmaceutical formulation according to any one of paragraphs 1, 1A to 14, wherein a loading dose in the range 400 to 900 mg, for example 400, 500, 600, 700, 800 or 900 mg is employed before administration of the treatment cycle.<br/>16. An antibody, antigen binding fragment or a pharmaceutical formulation according to any one of paragraphs 1, 1A to 14, wherein the treatment does not comprise a loading dose.<br/>17. An antibody or antigen binding fragment thereof according to any one of paragraphs 1 to 16, wherein the dose is 200 mg.<br/>18. An antibody, antigen binding fragment thereof or a pharmaceutical formulation according to paragraph 17, wherein the reduction in EASI is in the range &#x2212;15 to &#x2212;60% (for example at about day 15).<br/>19. An antibody, antigen binding fragment thereof or a pharmaceutical formulation according to paragraph 17 or 18 wherein the reduction in EASI score is in the range &#x2212;40 to &#x2212;85% (for example at about day 29).<br/>20. An antibody, antigen binding fragment thereof or a pharmaceutical formulation according to any one of paragraphs 17 to 19, wherein the reduction in EASI score is in the range &#x2212;25 to &#x2212;85% (for example at about day 43 or 57).<br/>21. An antibody, antigen binding fragment thereof or a pharmaceutical formulation according to any one of paragraphs 1, 1A to 16, wherein the dose is in the range 350 to 450 mg, such as 400 mg, for example wherein 80% of the patient population has an EASI 50 at about day 29 and/or day 57.<br/>22. An antibody, antigen binding fragment thereof or a pharmaceutical formulation according to any one of paragraphs 1 to 16, wherein the dose is 600 mg.<br/>23. An antibody, antigen binding fragment thereof or a pharmaceutical formulation according to paragraph 21 or 22, wherein the reduction in EASI score is in the range &#x2212;25 to &#x2212;60% (for example &#x2212;39 to &#x2212;59, such as &#x2212;40 to &#x2212;59, in particular &#x2212;47, &#x2212;48, &#x2212;49, &#x2212;50, &#x2212;51, &#x2212;52, &#x2212;53, &#x2212;54, &#x2212;55, &#x2212;56, &#x2212;57, &#x2212;58 or &#x2212;59%) for example at about day 15.<br/>24. An antibody, antigen binding fragment thereof or a pharmaceutical formulation according to any one of paragraphs 21 to 23, wherein the reduction in EASI score is in the range &#x2212;50 to &#x2212;100% (for example &#x2212;55 to &#x2212;97%) in particular at about day 29.<br/>25. An antibody, antigen binding fragment thereof or a pharmaceutical formulation according to any one of paragraphs 21 to 24, wherein the reduction in EASI score is in the range &#x2212;60 to &#x2212;100% (for example &#x2212;70 to &#x2212;97%) in particular at about day 43.<br/>26. An antibody, antigen binding fragment thereof or a pharmaceutical formulation according to any one of paragraphs 21 to 25, wherein the reduction in EASI score is in the range &#x2212;65 to &#x2212;100% (for example &#x2212;70 to &#x2212;100, such as &#x2212;90 to &#x2212;-100, in particular 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100%) in particular at about day 57.<br/>27. An antibody, binding fragment thereof or a pharmaceutical formulation according to any one of paragraphs 21 to 26, wherein 90% of the patient population has an EASI 50 at about day 57.<br/>28. An antibody, antigen binding fragment thereof or a pharmaceutical formulation according to any one of paragraphs 1, 1A to 26, wherein the treatment cycles comprises, a first dose at 600 mg, followed by three weekly doses of 400 mg, for example wherein the treatment cycle is repeated twice i.e. two treatment cycles lasting 8 weeks, in particular day 1 600 mg, approximately day 8 400 mg, approximately day 15 400 mg, approximately day 22 400 mg, approximately day 29 600 mg, approximately day 36 400 mg, approximately day 43 400 mg, and approximately day 50 400 mg are administered.<br/>29. An antibody, antigen binding fragment thereof or a pharmaceutical formulation according to any one of paragraphs 1, 1A to 28, wherein disease modification, occurs by day 4, wherein day 1 is the first administration of the antibody or binding fragment thereof.<br/>30. An antibody, antigen binding fragment or a pharmaceutical formulation according to paragraph 29, wherein the disease modification is a reduction in EASI score, for example wherein the reduction is a percentage from base line in the range &#x2212;10 to 55%.<br/>31. An antibody, antigen binding fragment thereof or a pharmaceutical formulation according to any one of paragraphs 1, 1A to 30, wherein the disease modification in the range &#x2212;40 to -100% is achieved by about day 57 following first administration on day 1, for example maximum disease modification is achieved by about day 57.<br/>32. An antibody, antigen binding fragment thereof or a pharmaceutical formulation for use according to any one of paragraphs 1, 1A to 30, wherein the antibody or binding fragment binds an epitope FFYQ (for example same epitope as the antibody with a VH shown in SEQ ID NO: 51 and a VL shown in SEQ ID NO: 53, or a sequence at least 95% identical to any one of the same.<br/>33. An antibody, antigen binding fragment thereof or a pharmaceutical formulation for use according to any one of paragraphs 1, 1A to 32, wherein the anti-IL-13R antibody comprises a VH CDR1 comprising an amino acid sequence as set forth in SEQ ID NO: 1, a VH CDR2 comprising an amino acid sequence as set forth in SEQ ID NO: 2, and a VH CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 10.<br/>34. An antibody, antigen binding fragment thereof or a pharmaceutical formulation for use according to any one of paragraphs 1, 1A to 33, wherein the anti-IL-13R antibody comprises a VH domain comprising an amino acid sequence shown in SEQ ID NO: 51 or a sequence at least 95% identical thereto, in particular SEQ ID NO: 51.<br/>35. An antibody or antigen binding fragment thereof for use according to any one of paragraphs 1, 1A to 34, wherein the anti-IL-13R antibody comprises a VL CDR1 comprising an amino acid sequence as set forth in SEQ ID NO: 31, a VL CDR2 comprising an amino acid sequence as set forth in SEQ ID NO: 32, and a VL CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 45.<br/>36. An antibody or antigen binding fragment thereof for use according to any one of paragraphs 1, 1A to 35, wherein the anti-IL-13R antibody comprises a VL domain comprising an amino acid sequence shown in SEQ ID NO: 53 or a sequence at least 95% identical thereto, in particular SEQ ID NO: 53.<br/>37. An antibody or antigen binding fragment thereof for use according to any one of paragraphs 1, 1A to 36, wherein the antibody is provided as a pharmaceutical formulation comprising</p><p id="p-0012" num="0010">10 to 140 mg/ml of the antibody or binding fragment;</p><p id="p-0013" num="0011">50 mM to 150 mM of arginine (for example 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145 or 150, such as 100 mM arginine);</p><p id="p-0014" num="0012">15 to 25 mM histidine buffer, for example 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 and 25, such as 20 mM histidine buffer;</p><p id="p-0015" num="0013">0.01-0.03% of a non-ionic surfactant, such as 0.02% w/v and</p><p id="p-0016" num="0014">wherein the pH of the formulation is in the range 5.5 to 7.5 for example 6.2 to 7.2 (such as 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2), such as 6.5 to 7.0, in particular 6.4 to 6.9)</p><p id="p-0017" num="0000">38. An antibody, antigen binding fragment thereof or a pharmaceutical formulation for use according to paragraph 37, wherein the osmolarity of the formulation is in the range 350 to 550 mOsmo/kg, for example 350, 355, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 515, 520, 525, 530, 535, 540, 545, 550, such as 405 to 435 mOsmo/kg.<br/>39. An antibody, antigen binding fragment thereof or a pharmaceutical formulation for use according to paragraphs 37 or 38, which further comprises 50 to 200 mM of a sugar, for example 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, such as 180 mM sugar.<br/>40. An antibody, antigen binding fragment or a pharmaceutical formulation for use according to any one of paragraphs 37 to 40, wherein the pH is 6.5.<br/>41. An antibody, antigen binding fragment thereof or a pharmaceutical formulation for use according to any one of paragraphs 37 to 40, wherein the formulation does not comprise NaCl.<br/>42. An antibody, antigen binding fragment thereof or a pharmaceutical formulation for use according to any one of paragraphs 37 to 41, wherein the formulation comprises 50 to 150 mM of NaCl, for example50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, such as 62.5 or 140 mM NaCl.<br/>43. A method of treating a patient for atopic dermatitis (for example moderate to severe atopic dermatitis, in particular poorly controlled moderate to severe atopic dermatitis) comprising administering parenterally an antibody, antigen binding fragment thereof or a pharmaceutical formulation, which is an inhibitor of signalling through of the IL-13R&#x3b1;1 by binding the said receptor (for example according to any one of paragraphs 1 to 42), such that the incidence of side effects in the eyes are reduced in comparison to treatment with the therapeutic dose of dupilumab for treatment of the same.<br/>44. Use of an antibody, antigen binding fragment or a pharmaceutical formulation, which is an inhibitor of signalling through of the IL-13R&#x3b1;1 by binding the said receptor, for example according to any one of paragraphs 1 to 42, for use in the manufacture of a medicament for the treatment of atopic dermatitis wherein the incidence of side effects in the eyes are reduced in comparison to treatment with the therapeutic dose of dupilumab for treatment of the same</p><p id="p-0018" num="0015">Also provided is method of treating a patient for atopic dermatitis (for example moderate to severe atopic dermatitis, in particular poorly controlled moderate to severe atopic dermatitis) according to the present disclosure comprising administering an antibody or antigen binding fragment thereof, or pharmaceutical formulation disclosed herein.</p><p id="p-0019" num="0016">In further aspect there is provided use of an antibody or antigen binding fragment or a pharmaceutical formulation disclosed herein for use in the manufacture of a medicament for the treatment of atopic dermatitis according to the present disclosure.</p><p id="p-0020" num="0017">In one embodiment there is a provided a reduction in the Investigator Global Assessment IGA with/after treatment according to the present disclosure, for example an assessment of 0, 1 or 2, (no inflammatory signs, almost clear and mild disease respectively). In particular there is provided an IGA score of 0 or 1.</p><p id="p-0021" num="0018">In one embodiment there is provided a reduction in percentage body surface area (%BSA) of atopic dermatitis (AD) involvement with/after treatment according to the present disclosure, for example a reduction of at least &#x2212;20% from the baseline (i.e. at least &#x2212;20% CFBL), such as a &#x2212;20%, &#x2212;30%, &#x2212;40%, &#x2212;50%, &#x2212;60%, &#x2212;70%, &#x2212;80%, &#x2212;90% or &#x2212;100% CFBL. In one embodiment, there is a reduction in percentage body surface area (% BSA) of AD involvement of &#x2212;40 to &#x2212;70%, such as &#x2212;40%, &#x2212;50%, &#x2212;60% or &#x2212;70%. In one embodiment, there is a reduction in % BSA of at least &#x2212;50%, such as &#x2212;50%, &#x2212;55%, &#x2212;60% or &#x2212;65%.</p><p id="p-0022" num="0019">In one embodiment combination therapy is employed comprising the antibody, antigen binding fragment thereof or a formulation according to the present disclosure and a further medicament. In one embodiment the further medicament is for the treatment of atopic dermatitis, for example topical steroids, oral steroids, and/or antihistamines.</p><p id="p-0023" num="0020">Surprisingly disease modification following treatment with an anti IL-13R&#x3b1;1 antibody or binding fragment thereof according to the present disclosure closely follows reduction in TARC, in fact the TARC reduction and EASI reduction seem to correlate closely.</p><heading id="h-0005" level="1">DETAILED DISCLOSURE</heading><p id="p-0024" num="0021">Disease modification as employed herein relates to improvements in the disease status, for example as measured by any suitable clinical parameter, in particular a reduction in the EASI score.</p><p id="p-0025" num="0022">A clinically relevant score is a score used in the clinical, for example used by a physician.</p><p id="p-0026" num="0023">In one embodiment the disease is modified by a percentage reduction in Eczema Area and Severity Index (EASI) score in the range &#x2212;20 to &#x2212;100% from the baseline, such as EASI 50, EASI 75 or EASI 90.</p><p id="p-0027" num="0024">EASI score and EASI are used interchangeably herein.</p><p id="p-0028" num="0025">Eczema Area and Severity Index (EASI) score as used herein is a tool used to measure the area (which indicates the extent of disease) and severity of atopic eczema. The number after the term &#x201c;EASI&#x201d; indicates the % decrease in the score from baseline. Thus, EASI 50 for example refers to 50% decrease in the score and EASI 90 refers to a 90% decrease in the score.</p><p id="p-0029" num="0026">In one embodiment disease modification is measured as a reduction in IGA.</p><p id="p-0030" num="0027">Investigator's global assessment (IGA) as used herein refers to a tool for the assessment of atopic dermatitis. It uses a 0-5 point scale depending on the severity of a patient's symptoms:</p><p id="p-0031" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="35pt" align="center"/><colspec colname="2" colwidth="70pt" align="left"/><colspec colname="3" colwidth="168pt" align="left"/><thead><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row><row><entry>Score</entry><entry>Severity</entry><entry>Description of symptoms</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="35pt" align="char" char="."/><colspec colname="2" colwidth="70pt" align="left"/><colspec colname="3" colwidth="168pt" align="left"/><tbody valign="top"><row><entry>0</entry><entry>clear</entry><entry>no inflammatory signs</entry></row><row><entry>1</entry><entry>almost clear</entry><entry>Just perceptible erythema and just perceptible</entry></row><row><entry/><entry/><entry>papulation/infiltration</entry></row><row><entry>2</entry><entry>mild disease</entry><entry>Mild erythema and mild papulation/infiltration</entry></row><row><entry>3</entry><entry>moderate disease</entry><entry>moderate erythema and moderate papulation/infiltration</entry></row><row><entry>4</entry><entry>severe disease</entry><entry>severe erythema and severe papulation/infiltration</entry></row><row><entry>5</entry><entry>very severe disease</entry><entry>severe erythema and severe papulation/infiltration with</entry></row><row><entry/><entry/><entry>oozing/crusting</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0032" num="0028">Body surface area (BSA) of atopic dermatitis (AD) involvement as used herein refers to a simple measure of percentage body surface area (%BSA) involved with atopic dermatitis, which does not incorporate disease severity.</p><p id="p-0033" num="0029">Patient Oriented Eczema Measure (POEM) as used herein refers to a 7-item questionnaire for patients that assesses presence of disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) over the last week using a scoring system of 0 (no days) to 4 (every day). The total score ranges from 0 to 28 with higher scores indicating greater intensity of eczema.</p><p id="p-0034" num="0030">Interleukin-13 receptor (IL-13R) as used herein is a type I cytokine receptor, which binds to Interleukin-13. It consists of two subunits, encoded by IL13R&#x3b1;1 and IL4R, respectively. These two genes encode the proteins IL-13R&#x3b1;1 and IL-4R&#x3b1;. These form a dimer with IL-13 binding to the IL-13R&#x3b1;1 chain and IL-4R&#x3b1; stabilises this interaction. Due to the presence of the IL4R subunit, IL13R can also instigate IL-4 signalling. In both cases this occurs via activation of the Janus kinase (JAK)/Signal Transducer and Activator of Transcription (STAT) pathway, resulting in phosphorylation of STATE. Human IL-13R&#x3b1;1 has the Uniprot number P3597.</p><p id="p-0035" num="0031">IL-13R&#x3b1;2, previously called IL-13R and IL-13R&#x3b1;, is another receptor which is able to bind to</p><p id="p-0036" num="0032">IL-13. However, in contrast to IL-13R&#x3b1;1, this protein binds IL-13 with high affinity, but it does not bind IL-4. Human IL-13R&#x3b1;2 has the Uniprot number Q14627.</p><p id="p-0037" num="0033">In one embodiment the anti-IL-13R antibody or binding fragment thereof of the present disclosure binds to IL-13R&#x3b1;1. In one embodiment, the antibody or binding fragment thereof binds only to IL-13R&#x3b1;1 and does not bind to IL-13R&#x3b1;2.</p><p id="p-0038" num="0034">In one embodiment CDRH1 comprises an amino acid sequence GYSFTSYWIG (SEQ ID NO: 1) as disclosed in WO2020/197502 incorporated herein by reference.</p><p id="p-0039" num="0035">In one embodiment CDRH2 comprises an amino acid sequence VIYPGDSYTR (SEQ ID NO: 2) as disclosed in WO2020/197502 incorporated herein by reference.</p><p id="p-0040" num="0036">In one embodiment CDRH3 comprises the formula:</p><p id="p-0041" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="42pt" align="left"/><colspec colname="1" colwidth="175pt" align="right"/><tbody valign="top"><row><entry/><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;3</entry></row><row><entry/><entry>X<sub>1</sub>&#x2003;Pro&#x2003;Asn&#x2003;Trp&#x2003;Gly&#x2003;X<sub>6</sub>&#x2003;X<sub>7</sub>&#x2003;Asp&#x2003;X<sub>9</sub></entry></row></tbody></tgroup></table></tables><ul id="ul0001" list-style="none">    <li id="ul0001-0001" num="0000">    <ul id="ul0002" list-style="none">        <li id="ul0002-0001" num="0037">X<sub>1 </sub>denotes Phe, Met, Gln, Leu or Val</li>        <li id="ul0002-0002" num="0038">X<sub>6 </sub>denotes Ser or Ala</li>        <li id="ul0002-0003" num="0039">X<sub>7 </sub>denotes Phe, Leu, Ala or Met</li>        <li id="ul0002-0004" num="0040">X<sub>9 </sub>denotes Tyr, Gln, Lys, Arg Trp, His, Ala, Thr, Ser, Asn or Gly<br/>In one embodiment the IL13-R1&#x3b1;1 antibody or binding fragment employed in the formulation of the present disclosure comprises a CDRH3 independently selected from a sequence comprising SEQ ID NO: 4 to 30.</li>    </ul>    </li></ul></p><p id="p-0042" num="0041">In one embodiment, the anti-IL13R antibody or binding fragment employed in the present disclosure comprises a VH CDR1 comprising an amino acid sequence as set forth in SEQ ID NO: 1, a VH CDR2 comprising an amino acid sequence as set forth in SEQ ID NO: 2, and a VH CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: or 3.</p><p id="p-0043" num="0042">In one embodiment, the anti-IL13R antibody or binding fragment employed in the present disclosure comprises a CDRH1 comprising an amino acid sequence as set forth in SEQ ID NO: 1, a CDRH2 comprising an amino acid sequence as set forth in SEQ ID NO: 2, and a CDRH3 comprising an amino acid sequence as set forth in SEQ ID NO: 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30.</p><p id="p-0044" num="0043">In one embodiment, the anti-IL13R antibody or binding fragment employed in the present disclosure comprises a CDRH1 comprising an amino acid sequence as set forth in SEQ ID NO: 1, a CDRH2 comprising an amino acid sequence as set forth in SEQ ID NO: 2, and a CDRH3 comprising an amino acid sequence as set forth in SEQ ID NO: 10.</p><p id="p-0045" num="0044">In one embodiment CDRL1 is an amino acid sequence comprising RASQSISSSYLA SEQ ID NO: 31.</p><p id="p-0046" num="0045">In one embodiment CDRL2 is an amino acid sequence comprising GASSRAT SEQ ID NO: 32</p><p id="p-0047" num="0046">In one embodiment CDL3 comprises the formula:</p><p id="p-0048" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="offset" colwidth="77pt" align="left"/><colspec colname="1" colwidth="140pt" align="left"/><tbody valign="top"><row><entry/><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;33</entry></row><row><entry/><entry>Gln&#x2003;X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>X<sub>5</sub></entry></row></tbody></tgroup></table></tables><ul id="ul0003" list-style="none">    <li id="ul0003-0001" num="0000">    <ul id="ul0004" list-style="none">        <li id="ul0004-0001" num="0047">X<sub>2 </sub>denotes Gln, Arg, Met, Ser, Thr or Val.</li>        <li id="ul0004-0002" num="0048">X<sub>3 </sub>denotes Tyr or Val.</li>        <li id="ul0004-0003" num="0049">X<sub>4 </sub>denotes Glu, Ala, Gly or Ser.</li>        <li id="ul0004-0004" num="0050">X<sub>5 </sub>denotes Thr, Ala or Ser.<br/>In one embodiment the IL-13R&#x3b1;1 antibody employed in the formulation of the present disclosure comprises a CDRL3 independently selected from a sequence comprising SEQ ID NO: 34 to 47:</li>    </ul>    </li></ul></p><p id="p-0049" num="0051">In one embodiment, the anti-IL-13R&#x3b1; antibody or binding fragment employed in the present disclosure comprises a CDRL1 comprising an amino acid sequence SEQ ID NO: 31, a CDRL2 comprising an amino acid sequence SEQ ID NO: 32, and a CDRL3 comprising an amino acid sequence as set forth in SEQ ID NO: 33.</p><p id="p-0050" num="0052">In one embodiment, the anti-IL-13R&#x3b1; antibody of the present disclosure comprises a VL CDR1 comprising an amino acid sequence SEQ ID NO: 31, a VL CDR2 comprising an amino acid sequence SEQ ID NO: 32, and a VL CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 34 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, or 47.</p><p id="p-0051" num="0053">In one embodiment, the anti-IL-13R&#x3b1; antibody of the present disclosure comprises a CDRL1 comprising an amino acid sequence SEQ ID NO: 31, a CDRL2 comprising an amino acid sequence SEQ ID NO: 32, and a CDRL3 comprising an amino acid sequence as set forth in SEQ ID NO: 45.</p><p id="p-0052" num="0054">In one embodiment, the anti-IL13R antibody of the present disclosure comprises a CDRH1 comprising an amino acid sequence as set forth in SEQ ID NO: 1, a CDRH2 comprising an amino acid sequence as set forth in SEQ ID NO: 2, and a CDRH3 comprising an amino acid sequence as set forth in SEQ ID NO: or 3, a CDRL1 comprising an amino acid sequence SEQ ID NO: 31, a CDRL2 comprising an amino acid sequence SEQ ID NO: 32, and a CDRL3 comprising an amino acid sequence as set forth in SEQ ID NO: 33.</p><p id="p-0053" num="0055">In one embodiment, the anti-IL13R antibody of the present disclosure comprises a CDRH1 comprising an amino acid sequence as set forth in SEQ ID NO: 1, a CDRH2 comprising an amino acid sequence as set forth in SEQ ID NO: 2, and a CDRH3 comprising an amino acid sequence as set forth in SEQ ID NO: 3 or 10, a CDRL1 comprising an amino acid sequence SEQ ID NO: 31, a CDRL2 comprising an amino acid sequence SEQ ID NO: 32, and a CDRL3 comprising an amino acid sequence as set forth in SEQ ID NO: 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, or 47.</p><p id="p-0054" num="0056">In one embodiment, the anti-IL13R antibody of the present disclosure comprises a CDRH1 comprising an amino acid sequence as set forth in SEQ ID NO: 1, a CDRH2 comprising an amino acid sequence as set forth in SEQ ID NO: 2, and a CDRH3 comprising an amino acid sequence as set forth in SEQ ID NO: 3 or 10, a CDRL1 comprising an amino acid sequence SEQ ID NO: 31, a CDRL2 comprising an amino acid sequence SEQ ID NO: 32, and a CDRL3 comprising an amino acid sequence as set forth in SEQ ID NO: 45.</p><p id="p-0055" num="0057">In one embodiment, the anti-IL13R antibody of the present disclosure comprises a CDRH1 comprising an amino acid sequence as set forth in SEQ ID NO: 1, a CDRH2 comprising an amino acid sequence as set forth in SEQ ID NO: 2, and a CDRH3 comprising an amino acid sequence as set forth in SEQ ID NO: 10, a CDRL1 comprising an amino acid sequence SEQ ID NO: 31, a CDRL2 comprising an amino acid sequence SEQ ID NO: 32, and a CDRL3 comprising an amino acid sequence as set forth in SEQ ID NO: 45.</p><p id="p-0056" num="0058">In one embodiment the VH region is independently selected from the group comprising: SEQ</p><p id="p-0057" num="0059">ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50 and SEQ ID NO: 51, or a sequence at least 95% identical to any one of the same, in particular any sequence independently selected from SEQ ID NO: 48, 49, 50 and 51.</p><p id="p-0058" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="right"/><tbody valign="top"><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;48</entry></row><row><entry>EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMG</entry></row><row><entry> </entry></row><row><entry>VIYPGDSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCAR</entry></row><row><entry> </entry></row><row><entry>FPNWGSFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;49</entry></row><row><entry>EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMG</entry></row><row><entry> </entry></row><row><entry>VIYPGDSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCAR</entry></row><row><entry> </entry></row><row><entry>MPNWGSFDYWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;50</entry></row><row><entry>EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMG</entry></row><row><entry> </entry></row><row><entry>VIYPGDSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCVR</entry></row><row><entry> </entry></row><row><entry>MPNWGSLDHWGQGTLVTVSS</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;51</entry></row><row><entry>EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMG</entry></row><row><entry> </entry></row><row><entry>VIYPGDSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCAR</entry></row><row><entry> </entry></row><row><entry>MPNWGSLDHWGQGTLVTVSS</entry></row></tbody></tgroup></table></tables></p><p id="p-0059" num="0060">In one embodiment the VL is independently selected from the group comprising SEQ ID NO: 52, SEQ ID NO: 53 and SEQ ID NO: 54, or a sequence at least 95% identical to any one of the same, in particular a sequence independently selected from SEQ ID NO: 52, 53 and 54.</p><p id="p-0060" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0" tabstyle="monospace"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="right"/><tbody valign="top"><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;52</entry></row><row><entry>EIVLTQSPGTLSLSPGERATLSCRASQSISSSYLAWYQQKPGQAPRLLIY</entry></row><row><entry> </entry></row><row><entry>GASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYETFGQGTK</entry></row><row><entry> </entry></row><row><entry>VEI*</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;53</entry></row><row><entry>EIVLTQSPGTLSLSPGERATLSCRASQSISSSYLAWYQQKPGQAPRLLIY</entry></row><row><entry> </entry></row><row><entry>GASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYASFGQGTK</entry></row><row><entry> </entry></row><row><entry>VEI*</entry></row><row><entry> </entry></row><row><entry>SEQ&#x2003;ID&#x2003;NO:&#x2003;54</entry></row><row><entry>EIVLTQSPGTLSLSPGERATLSCRASQSISSSYLAWYQQKPGQAPRLLIY</entry></row><row><entry> </entry></row><row><entry>GASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYEAFGQGTK</entry></row><row><entry> </entry></row><row><entry>VEI*</entry></row><row><entry> </entry></row><row><entry>(*K&#x2003;deleted&#x2003;in&#x2003;a&#x2003;post&#x2003;translational&#x2003;modification).</entry></row></tbody></tgroup></table></tables><br/>SEQ ID NO: 1 to 54 are disclosed in WO2020/197502 incorporated herein by reference.</p><p id="p-0061" num="0061">In one embodiment the VH sequence is SEQ ID NO: 48 (or a sequence at least 95% identical thereto) and the VL sequence is SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54 or SEQ ID NO: 55 (or a sequence at least 95% identical to any one of the same).</p><p id="p-0062" num="0062">In one embodiment the VH sequence is SEQ ID NO: 49 (or a sequence at least 95% identical thereto) and the VL sequence is SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54 or SEQ ID NO: 55 (or a sequence at least 95% identical to any one of the same).</p><p id="p-0063" num="0063">In one embodiment the VH sequence is SEQ ID NO: 50 (or a sequence at least 95% identical thereto) and the VL sequence is SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54 or SEQ ID NO: 55 (or a sequence at least 95% identical to any one of the same).</p><p id="p-0064" num="0064">In one embodiment the VH sequence is SEQ ID NO: 51 (or a sequence at least 95% identical thereto) and the VL sequence is SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54 or SEQ ID NO: 55 (or a sequence at least 95% identical to any one of the same).</p><p id="p-0065" num="0065">In one embodiment the VL sequence is SEQ ID NO: 52 (or a sequence at least 95% identical thereto) and the VH sequence is SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50 or SEQ ID NO: 51. (or a sequence at least 95% identical to any one of the same)</p><p id="p-0066" num="0066">In one embodiment the VL sequence is SEQ ID NO: 53 (or a sequence at least 95% identical thereto) and the VH sequence is SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50 or SEQ ID NO: 51 (or a sequence at least 95% identical to any one of the same).</p><p id="p-0067" num="0067">In one embodiment the VL sequence is SEQ ID NO: 54 (or a sequence at least 95% identical thereto) and the VH sequence is SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50 or SEQ ID NO: 51 (or a sequence at least 95% identical to any one of the same).</p><p id="p-0068" num="0068">In one embodiment the VH sequence is SEQ ID NO: 51 (or a sequence at least 95% identical thereto) and the VL sequence is SEQ ID NO: 53 ((or a sequence at least 95% identical thereto).</p><p id="p-0069" num="0069">Variable region as employed herein refers to the region in an antibody chain comprising the CDRs and a suitable framework.</p><p id="p-0070" num="0070">In one embodiment the heavy chain comprises a sequence independently selected from the group comprising SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59 and SEQ ID NO: 60, or a sequence at least 95% identical to any one of the same.</p><p id="p-0071" num="0071">Each SEQ ID NO: 55 to 60 have a post translational modification, which is deletion of K at the C terminal. SEQ ID NO: 55 to 60 are disclosed as SEQ ID NO: 56 to 61 in W02020/197502, incorporated herein by reference.</p><p id="p-0072" num="0072">SEQ ID NO: 61, 62 and 63 herein are disclosed in WO2020/197502, incorporated herein by reference, as SEQ ID NO: 62, 63 and 55.</p><p id="p-0073" num="0073">In one embodiment the heavy chain is independently selected from SEQ ID NO: 55, 56, 57, 58, 59, and 60 (or a sequence at least 95% identical to any one of the same) and the light chain is independently selected from SEQ ID NO: 61, 62 and 63 (or a sequence at least 95% identical to any one of the same).</p><p id="p-0074" num="0074">In one embodiment the heavy chain is SEQ ID NO: 55 (or a sequence at least 95% identical thereto) and the light chain is independently selected from SEQ ID NO: 61, 62 and 63 (or a sequence at least 95% identical to any one of the same).</p><p id="p-0075" num="0075">In one embodiment the heavy chain is SEQ ID NO: 56 (or a sequence at least 95% identical thereto) and the light chain is independently selected from SEQ ID NO: 61, 62 and 63 (or a sequence at least 95% identical to any one of the same).</p><p id="p-0076" num="0076">In one embodiment the heavy chain is SEQ ID NO: 57 (or a sequence at least 95% identical thereto) and the light chain is independently selected from SEQ ID NO: 61, 62 and 63 (or a sequence at least 95% identical to any one of the same).</p><p id="p-0077" num="0077">In one embodiment the heavy chain is SEQ ID NO: 58 (or a sequence at least 95% identical thereto) and the light chain is independently selected from SEQ ID NO: 61, 62 and 63 (or a sequence at least 95% identical to any one of the same).</p><p id="p-0078" num="0078">In one embodiment the heavy chain is SEQ ID NO: 59 (or a sequence at least 95% identical thereto) and the light chain is independently selected from SEQ ID NO: 61, 62 and 63 (or a sequence at least 95% identical to any one of the same).</p><p id="p-0079" num="0079">In one embodiment the heavy chain is SEQ ID NO: 60 (or a sequence at least 95% identical thereto) and the light chain is independently selected from SEQ ID NO: 61, 62 and 63 (or a sequence at least 95% identical to any one of the same).</p><p id="p-0080" num="0080">In one embodiment the heavy chain is SEQ ID NO: 58 or 60 (or a sequence at least 95% identical to any one of the same) and a light chain with the sequence shown in SEQ ID NO: 61 (or a sequence at least 95% identical thereto).</p><p id="p-0081" num="0081">In one embodiment the heavy chain is SEQ ID NO: 58 (or a sequence at least 95% identical to any one of the same) and a light chain with the sequence shown in SEQ ID NO: 61 (or a sequence at least 95% identical thereto).</p><p id="p-0082" num="0082">In one embodiment the heavy chain is SEQ ID NO: 60 (or a sequence at least 95% identical to any one of the same) and a light chain with the sequence shown in SEQ ID NO: 61 (or a sequence at least 95% identical thereto).</p><p id="p-0083" num="0083">Derived from as employed herein refers to the fact that the sequence employed or a sequence highly similar to the sequence employed was obtained from the original genetic material, such as the light or heavy chain of an antibody.</p><p id="p-0084" num="0084">&#x201c;At least 95% identical&#x201d; as employed herein is intended to refer to an amino acid sequence which over its full length is 95% identical or more to a reference sequence, such as 96, 97, 98 or 99% identical. Software programmes can be employed to calculate percentage identity.</p><p id="p-0085" num="0085">Any discussion of a protein, antibody or amino acid sequence herein will be understood to include any variants of the protein, antibody or amino acid sequence produced during manufacturing and/or storage. For example, during manufacturing or storage an antibody can be deamidated (e.g., at an asparagine or a glutamine residue) and/or have altered glycosylation and/or have a glutamine residue converted to pyroglutamate and/or have a N-terminal or C-terminal residue removed or &#x201c;clipped&#x201d; (C-terminal lysine residues of encoded antibodies are often removed during the manufacturing process) and/or have part or all of a signal sequence incompletely processed and, as a consequence, remain at the terminus of the antibody. It is understood that an antibody comprising a particular amino acid sequence or binding fragment thereof may be a heterogeneous mixture of the stated or encoded sequence and/or variants of that stated or encoded sequence or binding fragment thereof.</p><p id="p-0086" num="0086">In one embodiment the present disclosure extends to a sequence explicitly disclosed herein where the C-terminal lysine (K) has been cleaved.</p><p id="p-0087" num="0087">In one embodiment an antibody or binding fragment thereof, employed in a formulation of the present disclosure is humanised.</p><p id="p-0088" num="0088">Humanised (which include CDR-grafted antibodies) as employed herein refers to molecules having one or more complementarity determining regions (CDRs) from a non-human species and a framework region from a human immunoglobulin molecule (see eg U.S. Pat. No. 5,585,089 &#x26; WO91/09967). It will be appreciated that it may only be necessary to transfer the specificity determining residues of the CDRs rather than the entire CDR (see eg, Kashmiri et al., 2005, Methods, 36, 25-34). Humanised antibodies may optionally further comprise one or more framework residues derived from the non-human species from which the CDRs were derived. For a review, see Vaughan et al, Nature Biotechnology, 16, 535-539, 1998.</p><p id="p-0089" num="0089">When the CDRs or specificity determining residues are grafted, any appropriate acceptor variable region framework sequence may be used having regard to the class/type of the donor antibody from which the CDRs are derived, including mouse, primate and human framework regions. Examples of human frameworks which can be used in the present invention are KOL, NEWM, REI, EU, TUR, TEI, LAY and POM (Kabat et al.,). For example, KOL and NEWM can be used for the heavy chain, REI can be used for the light chain and EU, LAY and POM can be used for both the heavy chain and the light chain. Alternatively, human germline sequences may be used; these are available at: http://vbase.mrc-cpe.cam.ac.uk/</p><p id="p-0090" num="0090">In a humanised antibody employed in the present invention, the acceptor heavy and light chains do not necessarily need to be derived from the same antibody and may, if desired, comprise composite chains having framework regions derived from different chains.</p><p id="p-0091" num="0091">The framework regions need not have exactly the same sequence as those of the acceptor antibody. For instance, unusual residues may be changed to more frequently-occurring residues for that acceptor chain class or type. Alternatively, selected residues in the acceptor framework regions may be changed so that they correspond to the residue found at the same position in the donor antibody (see Reichmann et al., 1998, Nature, 332, 323-324). Such changes should be kept to the minimum necessary to recover the affinity of the donor antibody. A protocol for selecting residues in the acceptor framework regions which may need to be changed is set forth in WO91/09967.</p><p id="p-0092" num="0092">In one embodiment the anti-IL13R antibodies of the present disclosure are fully human, in particular one or more of the variable domains are fully human.</p><p id="p-0093" num="0093">Fully human molecules are those in which the variable regions and the constant regions (where present) of both the heavy and the light chains are all of human origin, or substantially identical to sequences of human origin, not necessarily from the same antibody. Examples of fully human antibodies may include antibodies produced, for example by the phage display methods described above and antibodies produced by mice in which the murine immunoglobulin variable and optionally the constant region genes have been replaced by their human counterparts e.g. as described in general terms in EP0546073, U.S. Pat. Nos. 5,545,806, 5,569,825, 5,625,126, 5,633,425, 5,661,016, 5,770,429, EP0438474 and EP0463151.</p><p id="p-0094" num="0094">Thus, the presently disclosed anti-IL13R antibody may comprise one or more constant regions, such as a naturally occurring constant domain or a derivate of a naturally occurring domain.</p><p id="p-0095" num="0095">A derivative of a naturally occurring domain as employed herein is intended to refer to where one, two, three, four or five amino acids in a naturally occurring sequence have been replaced or deleted, for example to optimize the properties of the domain such as by eliminating undesirable properties but wherein the characterizing feature(s) of the domain is/are retained.</p><p id="p-0096" num="0096">If desired an antibody for use in the present invention may be conjugated to one or more effector molecule(s). It will be appreciated that the effector molecule may comprise a single effector molecule or two or more such molecules so linked as to form a single moiety that can be attached to the antibodies of the present invention. Where it is desired to obtain an antibody fragment linked to an effector molecule, this may be prepared by standard chemical or recombinant DNA procedures in which the antibody fragment is linked either directly or indirectly including via a coupling agent to the effector molecule. Techniques for conjugating such effector molecules to antibodies are well known in the art (see, Hellstrom et al., Controlled Drug Delivery, 2nd Ed., Robinson et al., eds., 1987, pp. 623-53; Thorpe et al., 1982, Immunol. Rev., 62: 119-58 and Dubowchik et al , 1999, Pharmacology and Therapeutics, 83, 67-123). Particular chemical procedures include, for example, those described in WO93/06231, WO92/22583, WO89/00195, WO89/01476 and WO03/031581. Alternatively, where the effector molecule is a protein or polypeptide the linkage may be achieved using recombinant DNA procedures, for example as described in WO86/01533 and EP0392745.</p><p id="p-0097" num="0097">The term effector molecule as used herein includes, for example, biologically active proteins, for example enzymes, other antibody or antibody fragments, synthetic or naturally occurring polymers, nucleic acids and fragments thereof eg DNA, RNA and fragments thereof, radionuclides, particularly radioiodide, radioisotopes, chelated metals, nanoparticles and reporter groups such as fluorescent compounds or compounds which may be detected by NMR or ESR spectroscopy.</p><p id="p-0098" num="0098">Other effector molecules may include detectable substances useful for example in diagnosis. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive nuclides, positron emitting metals (for use in positron emission tomography), and nonradioactive paramagnetic metal ions. See generally U.S. Pat. No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics. Suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; suitable prosthetic groups include streptavidin, avidin and biotin; suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride and phycoerythrin; suitable luminescent materials include luminol; suitable bioluminescent materials include luciferase, luciferin, and aequorin; and suitable radioactive nuclides include 125I, 131I, 111In and 99Tc.</p><p id="p-0099" num="0099">In another example the effector molecule may increase the half-life of the antibody in vivo, and/or reduce immunogenicity of the antibody and/or enhance the delivery of an antibody across an epithelial barrier to the immune system. Examples of suitable effector molecules of this type include polymers, albumin, albumin binding proteins or albumin binding compounds such as those described in WO05/117984. Where the effector molecule is a polymer it may, in general, be a synthetic or a naturally occurring polymer, for example an optionally substituted straight or branched chain polyalkylene, polyalkenylene or polyoxyalkylene polymer or a branched or unbranched polysaccharide, e.g. a homo- or hetero- polysaccharide.</p><p id="p-0100" num="0100">Specific optional substituents which may be present on the above-mentioned synthetic polymers include one or more hydroxy, methyl or methoxy groups.</p><p id="p-0101" num="0101">Specific examples of synthetic polymers include optionally substituted straight or branched chain poly(ethyleneglycol), poly(propyleneglycol) poly(vinylalcohol) or derivatives thereof, especially optionally substituted poly(ethyleneglycol) such as methoxypoly(ethyleneglycol) or derivatives thereof.</p><p id="p-0102" num="0102">Specific naturally occurring polymers include lactose, amylose, dextran, glycogen or derivatives thereof.</p><p id="p-0103" num="0103">&#x201c;Derivatives&#x201d; as used herein is intended to include reactive derivatives, for example thiol-selective reactive groups such as maleimides and the like. The reactive group may be linked directly or through a linker segment to the polymer. It will be appreciated that the residue of such a group will in some instances form part of the product as the linking group between the antibody fragment and the polymer.</p><p id="p-0104" num="0104">Suitable polymers include a polyalkylene polymer, such as a poly(ethyleneglycol) or, especially, a methoxypoly(ethyleneglycol) or a derivative thereof, and especially with a molecular weight in the range from about 15000 Da to about 40000 Da.</p><p id="p-0105" num="0105">In one example antibodies for use in the present invention are attached to poly(ethyleneglycol) (PEG) moieties. In one particular example the antibody is an antibody fragment and the PEG molecules may be attached through any available amino acid side-chain or terminal amino acid functional group located in the antibody fragment, for example any free amino, imino, thiol, hydroxyl or carboxyl group. Such amino acids may occur naturally in the antibody fragment or may be engineered into the fragment using recombinant DNA methods (see for example U.S. Pat. Nos. 5,219,996; 55,667,425; WO98/25971, WO2008/038024). In one example the antibody molecule of the present invention is a modified Fab fragment wherein the modification is the addition to the C-terminal end of its heavy chain one or more amino acids to allow the attachment of an effector molecule. Suitably, the additional amino acids form a modified hinge region containing one or more cysteine residues to which the effector molecule may be attached. Multiple sites can be used to attach two or more PEG molecules.</p><p id="p-0106" num="0106">In patients with cancer, such as breast cancer, cancer related lymphedema (BCRL), the formulation of the present disclosure may prevent lymphedema-associated effects, such as fibrosis, hyperkeratosis, the deposition of fibroadipose tissue, fluid accumulation, limb swelling, reduction of skin elasticity, and pain. By reducing the excess volume, said formulation may improve lymphatic and, for example limb functions.</p><p id="p-0107" num="0107">The development of lympheclema after lymphatic injury is associated with tissue inflammation, the infiltration of CD4-positive cells and their differentiation to the type 2 helper T-cell (Th2) phenotype, Th2 cells produce IL-4 and IL-13 that play a key role in the development of lymphedema-associated symptoms as well as other Th2-mediated diseases.</p><p id="p-0108" num="0108">In one embodiment the formulation herein is administered in combination with another therapy.</p><p id="p-0109" num="0109">&#x201c;In combination&#x201d; as employed herein is intended to encompass where the anti-IL13R antibody is administered before, concurrently with another therapy or after another therapy, as the same or different formulations. Thus, combination is where the pharmacological effect of a first therapy exists at the same as the existence of a pharmacological effect of second therapy in the body and/or the two therapies are part of treatment plan designed to be employed together.</p><p id="p-0110" num="0110">Therapeutic dose as employed herein refers to the amount of the anti-IL13R antibody, such as ASLAN004, that is suitable for achieving the intended therapeutic effect when employed in a suitable treatment regimen, for example ameliorates symptoms or conditions of a disease, in particular without eliciting dose limiting side effects. Suitable therapeutic doses are generally a balance between therapeutic effect and tolerable toxicity, for example where the side-effect and toxicity are tolerable given the benefit achieved by the therapy.</p><p id="p-0111" num="0111">In one embodiment a formulation according to the present disclosure (including a formulation comprising same) is administered monthly, for example in a treatment cycle or as maintenance therapy.</p><p id="p-0112" num="0112">Unit dose as used herein generally refers to a product comprising the amount of anti-IL13R antibody or binding fragment thereof of the present disclosure that is administered in a single dose including any overage.</p><p id="p-0113" num="0113">A unit dose of the presently claimed anti-IL13R antibody or antigen binding fragment thereof may refer to the marketed form of the product, such as a formulation of the anti-IL13R antibody or binding fragment thereof, wherein the product is apportioned into the amount of anti-IL13R antibody that is required for a single dose. Thus, the manufacturer is able to determine and control the exact amount of anti-13R antibody or binding fragment thereof to be included in each unit dose.</p><p id="p-0114" num="0114">The product may be in various forms, familiar to the skilled addressee, such as vials, ampoules, infusion bags or a device (including an auto-injection device).</p><p id="p-0115" num="0115">The exact amount as employed herein refers to the amount to be administer as a dose to the patient and any overage.</p><p id="p-0116" num="0116">In one embodiment, the unit dose or unit doses are for use according to a method of the present disclosure.</p><p id="p-0117" num="0117">In the context of this specification &#x201c;comprising&#x201d; is to be interpreted as &#x201c;including&#x201d;. Embodiments of the invention comprising certain features/elements are also intended to extend to alternative embodiments &#x201c;consisting&#x201d; or &#x201c;consisting essentially&#x201d; of the relevant elements/features. Where technically appropriate, embodiments of the invention may be combined.</p><p id="p-0118" num="0118">Technical references such as patents and applications are incorporated herein by reference.</p><p id="p-0119" num="0119">Any embodiments specifically and explicitly recited herein may form the basis of a disclaimer either alone or in combination with one or more further embodiments.</p><p id="p-0120" num="0120">The background section of this specification contains relevant technical information and may be used as basis for amendment. Subject headings herein are employed to divide the document into sections and are not intended to be used to construe the meaning of the disclosure provided herein.</p><p id="p-0121" num="0121">The present specification claims priority from SG10202102086S (filed 01 Mar. 2021); SG10202110688T (filed 27 Sep. 2021) both incorporated herein by reference. These applications may be used as basis for corrections to the present specification, especially in respect of sequences disclosed therein.</p><p id="p-0122" num="0122">The present invention is further described by way of illustration only in the following examples.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0006" level="1">BRIEF DESCRIPTION OF FIGURES</heading><p id="p-0123" num="0123"><figref idref="DRAWINGS">FIG. <b>1</b>A</figref> Table showing demographics of full analysis set</p><p id="p-0124" num="0124"><figref idref="DRAWINGS">FIG. <b>1</b>B</figref> Table showing baseline disease characteristics of full analysis set</p><p id="p-0125" num="0125"><figref idref="DRAWINGS">FIG. <b>1</b>C</figref> Table showing baseline disease characteristics of Evaluable for Efficacy set (EES)</p><p id="p-0126" num="0126"><figref idref="DRAWINGS">FIG. <b>2</b>A</figref> Table showing % change from baseline in EASI score at Day 57 for EES</p><p id="p-0127" num="0127"><figref idref="DRAWINGS">FIG. <b>2</b>B</figref> Graph showing % change from baseline in EASI score at Day 57 for EES (ASLAN004 200 mg, 400 mg and 600 mg)</p><p id="p-0128" num="0128"><figref idref="DRAWINGS">FIG. <b>2</b>C</figref> Graph showing % change from baseline in EASI score at Day 57 for EES (ASLAN004 low dose and high doses)</p><p id="p-0129" num="0129"><figref idref="DRAWINGS">FIG. <b>3</b>A</figref> Table showing % change from baseline in EASI score at Day 29 for EES.</p><p id="p-0130" num="0130"><figref idref="DRAWINGS">FIG. <b>3</b>B</figref> Graph showing % change from baseline in EASI score at Day 29 for EES (ASLAN004 200 mg, 400 mg and 600 mg)</p><p id="p-0131" num="0131"><figref idref="DRAWINGS">FIG. <b>4</b>A</figref> Graph showing % change in EASI score over time for EES (ASLAN004 200 mg, 400 mg and 600 mg)</p><p id="p-0132" num="0132"><figref idref="DRAWINGS">FIG. <b>4</b>B</figref> Graph showing % change in EASI score over time for EES (ASLAN004 low and high dose)</p><p id="p-0133" num="0133"><figref idref="DRAWINGS">FIG. <b>5</b>A</figref> Graph showing % change in baseline in EASI score over time for EES (Placebo)</p><p id="p-0134" num="0134"><figref idref="DRAWINGS">FIG. <b>5</b>B</figref> Graph showing % change in baseline in EASI score over time for EES (ASLAN004 200 mg)</p><p id="p-0135" num="0135"><figref idref="DRAWINGS">FIG. <b>5</b>C</figref> Graph showing % change in baseline in EASI score over time for EES (ASLAN004 400 mg)</p><p id="p-0136" num="0136"><figref idref="DRAWINGS">FIG. <b>5</b>D</figref> Graph showing % change in baseline in EASI score over time for EES (ASLAN004 600 mg)</p><p id="p-0137" num="0137"><figref idref="DRAWINGS">FIG. <b>6</b>A</figref> Table showing Day 57 sensitivity analysis in the modified intention to treat (mITT)</p><p id="p-0138" num="0138"><figref idref="DRAWINGS">FIG. <b>6</b>B</figref> Graph showing Day 57 sensitivity analysis in the mITT (ASLAN004 200 mg, 400 mg and 600 mg)</p><p id="p-0139" num="0139"><figref idref="DRAWINGS">FIG. <b>6</b>C</figref> Graph showing Day 57 sensitivity analysis in the mITT (ASLAN004 low and high dose)</p><p id="p-0140" num="0140"><figref idref="DRAWINGS">FIG. <b>7</b>A</figref> Summary table showing EASI 50, EASI 75, EASI 90 at Day 57 for EES</p><p id="p-0141" num="0141"><figref idref="DRAWINGS">FIG. <b>7</b>B</figref> Graph showing EASI 50 at Day 57 for EES (ASLAN004 200 mg, 400 mg and 600 mg)</p><p id="p-0142" num="0142"><figref idref="DRAWINGS">FIG. <b>7</b>C</figref> Graph showing EASI 50 at Day 57 for EES (ASLAN004 low and high dose)</p><p id="p-0143" num="0143"><figref idref="DRAWINGS">FIG. <b>7</b>D</figref> Graph showing EASI 75 at Day 57 for EES (ASLAN004 200 mg, 400 mg and 600 mg)</p><p id="p-0144" num="0144"><figref idref="DRAWINGS">FIG. <b>7</b>E</figref> Graph showing EASI 75 at Day 57 for EES (ASLAN004 low and high dose)</p><p id="p-0145" num="0145"><figref idref="DRAWINGS">FIG. <b>7</b>F</figref> Graph showing EASI 90 at Day 57 for EES (ASLAN004 200 mg, 400 mg and 600 mg)</p><p id="p-0146" num="0146"><figref idref="DRAWINGS">FIG. <b>7</b>G</figref> Graph showing EASI 90 at Day 57 for EES (ASLAN004 low and high dose)</p><p id="p-0147" num="0147"><figref idref="DRAWINGS">FIG. <b>8</b>A</figref> Graph showing proportion of patients achieving EASI 50</p><p id="p-0148" num="0148"><figref idref="DRAWINGS">FIG. <b>8</b>B</figref> Graph showing proportion of patients achieving EASI 75</p><p id="p-0149" num="0149"><figref idref="DRAWINGS">FIG. <b>8</b>C</figref> Graph showing proportion of patients achieving EASI 90</p><p id="p-0150" num="0150"><figref idref="DRAWINGS">FIG. <b>9</b></figref> Summary table showing proportion of patients achieving EAS ISO, 75, 90 for EES and mITT</p><p id="p-0151" num="0151"><figref idref="DRAWINGS">FIG. <b>10</b>A</figref> Summary table showing proportion of patients with IGA score of 0 or 1 at Day 57 for ESS</p><p id="p-0152" num="0152"><figref idref="DRAWINGS">FIG. <b>10</b>B</figref> Graph showing proportion of patients with IGA score of 0 or 1 at Day 57 for ESS</p><p id="p-0153" num="0153"><figref idref="DRAWINGS">FIG. <b>10</b>C</figref> Graph showing proportion of patients with IGA score of 0 or 1 over time for ESS</p><p id="p-0154" num="0154"><figref idref="DRAWINGS">FIG. <b>11</b></figref> Table showing baseline TARC and IgE levels of patients</p><p id="p-0155" num="0155"><figref idref="DRAWINGS">FIG. <b>12</b>A</figref> Graph showing average % change from baseline TARC (ASLAN004 200 mg and 400 mg)</p><p id="p-0156" num="0156"><figref idref="DRAWINGS">FIG. <b>12</b>B</figref> Graph showing average % change from baseline TARC (ASLAN004 400 mg and placebo)</p><p id="p-0157" num="0157"><figref idref="DRAWINGS">FIG. <b>12</b>C</figref> Graph showing % change from baseline TARC for individual patients (ASLAN004 400 mg)</p><p id="p-0158" num="0158"><figref idref="DRAWINGS">FIG. <b>13</b>A</figref> Graph showing IgE % change from baseline for ASLAN004 200 mg and 400 mg</p><p id="p-0159" num="0159"><figref idref="DRAWINGS">FIG. <b>13</b>B</figref> Graph showing average IgE% change from baseline for ASLAN004 200 mg and 400 mg</p><p id="p-0160" num="0160"><figref idref="DRAWINGS">FIG. <b>13</b>C</figref> Graph showing IgE % change from baseline for individual patients for placebo</p><p id="p-0161" num="0161"><figref idref="DRAWINGS">FIG. <b>13</b>D</figref> Graph showing IgE % change from baseline for individual patients for ASLAN004 200 mg</p><p id="p-0162" num="0162"><figref idref="DRAWINGS">FIG. <b>13</b>E</figref> Graph showing IgE % CFB for individual patients for ASLAN004 400 mg</p><p id="p-0163" num="0163"><figref idref="DRAWINGS">FIG. <b>14</b></figref> Graph showing comparison between ASLAN004 exposure, EASI, TARC and IgE over time for patients receiving ASLAN004 400 mg</p><p id="p-0164" num="0164"><figref idref="DRAWINGS">FIG. <b>15</b></figref> Table showing comparison in activity between ASLAN004 and Duplilumab</p><p id="p-0165" num="0165"><figref idref="DRAWINGS">FIG. <b>16</b></figref> Flow chart showing number of subjects in each test group</p><p id="p-0166" num="0166"><figref idref="DRAWINGS">FIG. <b>17</b></figref> Table showing baseline demographics and disease characteristics of Intention-to-treat (ITT), modified Intention-to-treat (mITT) and Excluded site groups</p><p id="p-0167" num="0167"><figref idref="DRAWINGS">FIG. <b>18</b></figref> Table showing adverse events (AEs) for mITT vs Excluded site groups</p><p id="p-0168" num="0168"><figref idref="DRAWINGS">FIG. <b>19</b></figref> Graph showing EASI, mean % change from baseline (%CFBL) for mITT group</p><p id="p-0169" num="0169"><figref idref="DRAWINGS">FIG. <b>20</b></figref> Graph showing EASI, mean % change from baseline (%CFBL) at week 8 for mITT vs Excluded site groups</p><p id="p-0170" num="0170"><figref idref="DRAWINGS">FIG. <b>21</b></figref> Graph showing placebo adjusted means (EASI) for mITT vs Excluded site groups</p><p id="p-0171" num="0171"><figref idref="DRAWINGS">FIG. <b>22</b></figref> Graph showing % of patients achieving EASI-50, EASI-75 and EAS-90 at week 8 for mITT group</p><p id="p-0172" num="0172"><figref idref="DRAWINGS">FIG. <b>23</b></figref> Graph showing % of patients achieving IGA 0/1 at week 8 for mITT group</p><p id="p-0173" num="0173"><figref idref="DRAWINGS">FIG. <b>24</b></figref> Graph showing mean % CFBL in % BSA affected for mITT group</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0007" level="1">EXAMPLES</heading><heading id="h-0008" level="1">Example 1 Study Protocol (Initial MAD Escalation)</heading><p id="p-0174" num="0174">Patients enrolled in ascending dose cohorts of ASLAN004 (SEQ ID NO: 51, 53 and 59 herein): 200 mg 400 mg, 600 mg. ASLAN low dose=ASLAN004 200 mg ASLAN high dose=ASLAN004 400 mg+ASLAN004 600 mg.<br/>Details of patients are shown in <figref idref="DRAWINGS">FIG. <b>1</b></figref>. Initially the doses were given weekly (QW). Within each cohort, patients were randomized in a 3:1 ratio of ASLAN004: Placebo</p><heading id="h-0009" level="1">Results</heading><p id="p-0175" num="0175">Table 1 shows the % change in baseline in EASI score at Day 57 (8 weeks).</p><p id="p-0176" num="0000"><tables id="TABLE-US-00006" num="00006"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 1</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>% change in baseline in EASI score at Day 57 (8 weeks)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="91pt" align="left"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="49pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry/><entry>Diff (vs. </entry></row><row><entry/><entry>Treatment Arm</entry><entry>N</entry><entry>Mean</entry><entry>Placebo)</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="91pt" align="left"/><colspec colname="2" colwidth="28pt" align="char" char="."/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="49pt" align="center"/><tbody valign="top"><row><entry/><entry>Placebo</entry><entry>5</entry><entry>&#x2212;42.4%</entry><entry>&#x2014;</entry></row><row><entry/><entry>ASLAN004 200 mg QW</entry><entry>4</entry><entry>&#x2212;49.5%</entry><entry>&#x2002;&#x2212;7.1%</entry></row><row><entry/><entry>ASLAN004 400 mg QW</entry><entry>6</entry><entry>&#x2212;73.6%</entry><entry>&#x2212;31.2%</entry></row><row><entry/><entry>ASLAN004 600 mg QW</entry><entry>3</entry><entry>&#x2212;75.8%</entry><entry>&#x2212;33.4%</entry></row><row><entry/><entry>ASLAN004 High Doses</entry><entry>9</entry><entry>&#x2212;74.3%</entry><entry>&#x2212;31.9%</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables><br/><figref idref="DRAWINGS">FIGS. <b>2</b>B to <b>2</b>C</figref> shows the %change in baseline in EASI score in graph form.<br/>Table 2 shows the % change in baseline in EASI score at Day 29 (4 weeks).</p><p id="p-0177" num="0000"><tables id="TABLE-US-00007" num="00007"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 2</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>% change in baseline in EASI score at Day 29 (4 weeks)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="49pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry/><entry>Diff (vs. </entry></row><row><entry/><entry>Treatment Arm</entry><entry>N</entry><entry>Mean</entry><entry>Placebo)</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="35pt" align="char" char="."/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="49pt" align="center"/><tbody valign="top"><row><entry/><entry>Placebo</entry><entry>5</entry><entry>&#x2212;30.5%</entry><entry>&#x2014;</entry></row><row><entry/><entry>ASLAN004 200 mg</entry><entry>4</entry><entry>&#x2212;51.2%</entry><entry>&#x2212;20.7%</entry></row><row><entry/><entry>ASLAN004 400 mg</entry><entry>6</entry><entry>&#x2212;63.7%</entry><entry>&#x2212;33.2%</entry></row><row><entry/><entry>ASLAN004 600 mg</entry><entry>3</entry><entry>&#x2212;53.6%</entry><entry>&#x2212;23.1%</entry></row><row><entry/><entry>ASLAN004 High Doses</entry><entry>9</entry><entry>&#x2212;60.4%</entry><entry>&#x2212;29.8%</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables><br/><figref idref="DRAWINGS">FIG. <b>3</b>B</figref> shows the %change in baseline in EASI score in graph form.<br/><figref idref="DRAWINGS">FIGS. <b>4</b> and <b>5</b></figref> show the % change in baseline in EASI score over time.<br/>Table 3 shows the sensitivity analysis in the mITT (modified intention to treat) set at Day 57</p><p id="p-0178" num="0000"><tables id="TABLE-US-00008" num="00008"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 3</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Sensitivity analysis in the mITT at Day 57</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="63pt" align="left"/><colspec colname="3" colwidth="28pt" align="center"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry/><entry>Diff (vs. </entry></row><row><entry>Analysis Set</entry><entry>Treatment Arm</entry><entry>N</entry><entry>Mean</entry><entry>Placebo)</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="56pt" align="left"/><colspec colname="2" colwidth="63pt" align="left"/><colspec colname="3" colwidth="28pt" align="char" char="."/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><tbody valign="top"><row><entry>EES </entry><entry>Placebo</entry><entry>5</entry><entry>&#x2212;42.9%</entry><entry>&#x2014;</entry></row><row><entry>(Primary)</entry><entry>ASLAN004 200 mg</entry><entry>4</entry><entry>&#x2212;49.5%</entry><entry>&#x2002;&#x2212;7.1%</entry></row><row><entry/><entry>ASLAN004 400 mg</entry><entry>6</entry><entry>&#x2212;73.6%</entry><entry>&#x2212;31.2%</entry></row><row><entry/><entry>ASLAN004 600 mg</entry><entry>3</entry><entry>&#x2212;75.8%</entry><entry>&#x2212;33.4%</entry></row><row><entry>mITT </entry><entry>Placebo</entry><entry>6</entry><entry>&#x2212;31.4%</entry><entry>&#x2014;</entry></row><row><entry>(sensitivity)</entry><entry>ASLAN004 200 mg</entry><entry>4</entry><entry>&#x2212;49.5%</entry><entry>&#x2212;18.9%</entry></row><row><entry/><entry>ASLAN004 400 mg</entry><entry>7</entry><entry>&#x2212;63.1%</entry><entry>&#x2212;31.6%</entry></row><row><entry/><entry>ASLAN004 600 mg</entry><entry>5</entry><entry>&#x2212;47.1%</entry><entry>&#x2212;15.7%</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables><br/><figref idref="DRAWINGS">FIG. <b>6</b>B</figref> to C shows the sensitivity analysis in graph form.<br/>Table 4 shows a summary of the proportion of patients achieving EASI 50, EASI 75 and EASI 90 at Day 57.</p><p id="p-0179" num="0000"><tables id="TABLE-US-00009" num="00009"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 4</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>EASI 50, EASI 75 and EASI 90 at Day 57</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="77pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="28pt" align="center"/><colspec colname="4" colwidth="56pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>EASI 50</entry><entry>EASI 75</entry><entry>EASI 90</entry></row><row><entry/><entry>Treatment Group</entry><entry>N (%)</entry><entry>N (%)</entry><entry>N (%)</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="77pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="28pt" align="char" char="."/><colspec colname="4" colwidth="56pt" align="char" char="."/><tbody valign="top"><row><entry/><entry>Placebo (n = 5)</entry><entry>2</entry><entry>0</entry><entry>0</entry></row><row><entry/><entry/><entry>(40.0%)</entry><entry/><entry/></row><row><entry/><entry>ASLAN004 200 </entry><entry>2</entry><entry>2</entry><entry>0</entry></row><row><entry/><entry>mg (n = 4)</entry><entry>(50.0%)</entry><entry>(50.0%)</entry><entry/></row><row><entry/><entry>ASLAN004 400 </entry><entry>5</entry><entry>4</entry><entry>4</entry></row><row><entry/><entry>mg (n = 6)</entry><entry>(83.3%)</entry><entry>(66.7%)</entry><entry>(66.7%)</entry></row><row><entry/><entry>ASLAN004 600 </entry><entry>3</entry><entry>2</entry><entry>1</entry></row><row><entry/><entry>mg (n = 3)</entry><entry>(100%)</entry><entry>(66.7%)</entry><entry>(33.3%)</entry></row><row><entry/><entry>ASLAN004 High </entry><entry>8</entry><entry>6</entry><entry>1</entry></row><row><entry/><entry>Doses (n = 9)</entry><entry>(88.9%)</entry><entry>(66.7%)</entry><entry>(55.6%)</entry></row><row><entry/><entry namest="offset" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables><br/><figref idref="DRAWINGS">FIGS. <b>7</b>B to <b>8</b>C</figref> shows the same data in graph form.<br/><figref idref="DRAWINGS">FIG. <b>9</b></figref> shows the proportion of miTT sensitivity analysis set achieving EASI 50, EASI 75 and EASI 90 at Day 57.<br/>Finally, <figref idref="DRAWINGS">FIG. <b>15</b></figref> shows a comparison between the proportion of patients achieving EASI 50, EASI 75 and EASI 90 at Day 57 when treated with ASLAN004 vs dupilumab.<br/>The results indicate that ASLAN004 results in a significant improvement in EASI score compared to placebo. In particular, at week 8, the average reduction in EASI from baseline at therapeutic doses (400 mg and 600 mg cohorts) was 74% (n=9) compared to 42% (n=5) for patients on placebo.<ul id="ul0005" list-style="none">    <li id="ul0005-0001" num="0000">    <ul id="ul0006" list-style="none">        <li id="ul0006-0001" num="0176">89% achieved EASI-50 versus 40% on placebo;</li>        <li id="ul0006-0002" num="0177">67% achieved EASI-75 versus 0% on placebo;</li>        <li id="ul0006-0003" num="0178">56% achieved EASI-90 versus 0% on placebo<br/>The results further suggest that ASLAN004 has a comparable or in some cases a higher efficacy compared to Dupilumab, thus demonstrating the potential of ASLAN004 as an alternative therapy for the treatment and management of atopic dermatitis.</li>    </ul>    </li></ul></p><heading id="h-0010" level="1">Example 2</heading><p id="p-0180" num="0179">In the 32 patients that completed at least 29 days of dosing across all sites, defined in the protocol as the efficacy evaluable data set, the average reduction from baseline in EASI at 8 weeks was 73% (n=19) compared to 44% (n=13) for patients on placebo (p=0.007<sup>1</sup>).</p><p id="p-0181" num="0180">The proportion of patients with adverse events and treatment-related adverse events were similar across treatment and placebo arms. There were no incidences of conjunctivitis in the expansion cohort.</p><p id="p-0182" num="0000"><tables id="TABLE-US-00010" num="00010"><table frame="none" colsep="0" rowsep="0" pgwide="1"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="259pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 5</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>EASI score for RITT and ITT groups</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="84pt" align="left"/><colspec colname="1" colwidth="91pt" align="center"/><colspec colname="2" colwidth="84pt" align="center"/><tbody valign="top"><row><entry/><entry>RITT (n = 29)</entry><entry>ITT (n = 38)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="35pt" align="center"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="28pt" align="center"/><colspec colname="6" colwidth="28pt" align="center"/><colspec colname="7" colwidth="28pt" align="center"/><tbody valign="top"><row><entry/><entry>600 mg</entry><entry>Placebo</entry><entry/><entry>600 mg</entry><entry>Placebo</entry><entry/></row><row><entry>Endpoint</entry><entry>(n = 16)</entry><entry>(n = 13)</entry><entry>p-value<sup>1</sup></entry><entry>(n = 22)</entry><entry>(n = 16)</entry><entry>p-value<sup>1</sup></entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="28pt" align="char" char="."/><colspec colname="3" colwidth="35pt" align="char" char="."/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="28pt" align="char" char="."/><colspec colname="6" colwidth="28pt" align="char" char="."/><colspec colname="7" colwidth="28pt" align="center"/><tbody valign="top"><row><entry>Mean % change from</entry><entry>&#x2212;64.9</entry><entry>&#x2212;27.2</entry><entry>0.021</entry><entry>&#x2212;61.3</entry><entry>&#x2212;31.9</entry><entry>0.023</entry></row><row><entry>baseline in EASI</entry></row><row><entry>EASI-50 (%)</entry><entry>81.3</entry><entry>30.8</entry><entry>0.008</entry><entry>77.3</entry><entry>37.5</entry><entry>0.016</entry></row><row><entry>EASI-75 (%)</entry><entry>68.8</entry><entry>15.4</entry><entry>0.005</entry><entry>50.0</entry><entry>12.5</entry><entry>0.018</entry></row><row><entry>EASI-90 (%)</entry><entry>37.5</entry><entry>15.4</entry><entry>0.183</entry><entry>27.3</entry><entry>12.5</entry><entry>0.245</entry></row><row><entry>IGA 0/1 (%)</entry><entry>43.8</entry><entry>15.4</entry><entry>0.107</entry><entry>31.8</entry><entry>18.8</entry><entry>0.301</entry></row><row><entry>Mean % change from</entry><entry>&#x2212;38.6</entry><entry>&#x2212;15.3</entry><entry>0.051</entry><entry>&#x2212;37.1</entry><entry>&#x2212;15.7</entry><entry>0.032</entry></row><row><entry>baseline in peak pruritis</entry></row><row><entry>Numerical Rating Scale</entry></row><row><entry>Mean change from</entry><entry>&#x2212;9.8</entry><entry>&#x2212;2.5</entry><entry>0.007</entry><entry>&#x2212;9.0</entry><entry>&#x2212;3.5</entry><entry>0.014</entry></row><row><entry>baseline in POEM</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row><row><entry namest="1" nameend="7" align="left" id="FOO-00001"><sup>1</sup>One-sided p-value</entry></row></tbody></tgroup></table></tables></p><p id="p-0183" num="0181">ASLAN004 achieved a statistically significant improvement (p&#x3c;0.025) versus placebo in the primary efficacy endpoint of percent change from baseline in the Eczema Area Severity Index (EASI), and also showed significant improvements (p&#x3c;0.05) in other key efficacy endpoints: EASI-50, EASI-75, peak pruritis and the Patient-Oriented Eczema Measure (POEM).</p><p id="p-0184" num="0182">Following discussions with the Data Monitoring Committee prior to unblinding, a Revised ITT population (RITT, n=29) was defined to exclude one study site at which all patients enrolled in the study appeared atypical of moderate-to-severe AD patients based on biomarkers, such as TARC, and patient medical history. In the RITT population, which is more comparable to other published studies in moderate-to-severe AD, ASLAN004 also achieved a statistically significant improvement (p&#x3c;0.025) versus placebo in percent change from baseline in EASI and showed a greater improvement over placebo in the key efficacy endpoints versus the ITT population.</p><heading id="h-0011" level="1">Example 3</heading><p id="p-0185" num="0183">The objective of this study was to further analyze secondary endpoints of clinical relevance and post hoc subgroup analyses.</p><heading id="h-0012" level="1">Methods</heading><p id="p-0186" num="0184">Three patient cohorts were randomized to receive either 200, 400 or 600 mg eblasakimab or placebo subcutaneously once weekly for 8 weeks in a multiple ascending dose study design.</p><p id="p-0187" num="0185">Adult patients were included with chronic AD present for years before screening, and the following atopic dermatitis (AD) parameters at screening and baseline: eczema area and severity index (EASI) 16, Investigator's Global Assessment (IGA) score (scale of 0 to 4), and 10% body surface area (BSA) of AD involvement. Rescue medication (moisturizer with active ingredient, topical corticosteroids, topical calcineurin inhibitors) was not allowed; LOCF was used for participants who used rescue med.</p><p id="p-0188" num="0186">Efficacy assessments included percent change from baseline (%CFBL) in EASI, proportions of patients with 50% or 75% improvement in EASI score (EASI 50 or EASI 75) or IGA 0/1, and % CFBL in percent BSA involvement. Further data are presented from a prespecified subgroup of patients from an excluded site with atypical AD.</p><p id="p-0189" num="0187">Inferential statistical analysis was performed for 600 mg vs. placebo groups at week 8 only; results for 200 and 400 mg groups were descriptively described due to small sample size.</p><p id="p-0190" num="0188">Efficacy analysis in the Phase 1b study used a modified Intent to Treat (mITT) population in which 9 study patients from one site were excluded (excluded site group) from the ITT analysis prior to unblinding as the participants did not have disease characteristics consistent with moderate to severe AD (<figref idref="DRAWINGS">FIG. <b>16</b></figref>).</p><heading id="h-0013" level="1">Results</heading><p id="p-0191" num="0189">The Excluded site set was markedly different from the mITT set at baseline with substantially lower serum TARC/CCL17 (7,350 pg/mL and 461 pg/mL, respectively), serum IgE (12,225 kU/I vs 527 kU/I), and EASI scores (mean 31.2 vs 19.3) showing lower extent and severity of disease. Other notable differences included older age, and lower IGA and BSA. Participants in this site had no atopic disease history but reported other comorbidities including diabetes and hypertension (<figref idref="DRAWINGS">FIG. <b>17</b></figref>).</p><p id="p-0192" num="0190">In the mITT analysis set, improvements in EASI score were seen early and progressed over the trial duration with eblasakimab treatment compared with placebo, with the 400 and 600 mg doses producing a great magnitude of response than the 200 mg dose (<figref idref="DRAWINGS">FIG. <b>19</b></figref>).</p><p id="p-0193" num="0191">Significant improvements in %CFBL in EASI score at week 8 were noted for eblasakimab 600 mg vs. placebo in the mITT set (&#x2212;65% vs. &#x2212;27%, P=0.014), but not the Excluded site population (<figref idref="DRAWINGS">FIG. <b>20</b></figref>). The difference in adjusted means was apparent early for the mITT set by week 6 but not for the Excluded site set (<figref idref="DRAWINGS">FIG. <b>21</b></figref>).</p><p id="p-0194" num="0192">Though the study was not powered to achieve statistical significance in any of the binary outcomes, improvements were nonetheless observed in the mITT set in the proportions of patients taking eblasakimab who achieved EASI-50, EASI-75 and EASI-90 over time vs. placebo at week 8 (EASI-50: 81% vs. 31%; EASI-75: 69% vs. 15%; EASI-90: 38% vs. 15%) (<figref idref="DRAWINGS">FIG. <b>4</b></figref>). No such improvement was apparent in the Excluded site*population.</p><p id="p-0195" num="0193">A higher percentage of patients achieved an IGA 0/1 at week 8 for eblasakimab 600 mg vs placebo in the mITT set (44% vs. 15%, P=0.107) but not the Excluded site population (<figref idref="DRAWINGS">FIG. <b>23</b></figref>).</p><p id="p-0196" num="0194">Mean % CFBL in BSA at week 8 was &#x2212;51% for eblasakimab 600 mg vs. &#x2212;13% for placebo in the mITT set and &#x2212;39% vs. &#x2212;44% in the Excluded site population (<figref idref="DRAWINGS">FIG. <b>24</b></figref>).</p><p id="p-0197" num="0195">Rescue medication use was low, but higher in the placebo group (data not shown). Rates of moderate-to-severe Adverse events (AEs) were comparable between 600 mg and placebo. AEs related to treatment were similar between groups (<figref idref="DRAWINGS">FIG. <b>18</b></figref>).</p><p id="p-0198" num="0196">Interestingly, AEs leading to treatment discontinuation were higher in the placebo group. 1 serious adverse event (SAE) reported in the study (mild abdominal pain, 400 mg); considered unrelated to treatment. No deaths were reported.</p><heading id="h-0014" level="1">CONCLUSION</heading><p id="p-0199" num="0197">This study indicates that eblasakimab was well tolerated with significant improvements vs. placebo in several efficacy outcomes in a Phase 1b study in adults with moderate to severe AD. Robustness of the data from the small study was supported by sensitivity analyses on the primary analysis set Including the Excluded site data did not change the primary endpoint or conclusions.</p><p id="p-0200" num="0198">That these significant improvements were seen within the 8-week study period offers the potential for a greater magnitude of effect with prolonged treatment, supporting further investigation in an ongoing Phase 2b clinical trial.</p><?detailed-description description="Detailed Description" end="tail"?></description><us-sequence-list-doc id="SEQLST-1"><sequence-list file="US20230002484A1-20230105-S00001.XML" carriers="internal-electronic" seq-file-type="ST.26"/></us-sequence-list-doc><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A method of treating a patient to reduce EASI score in the range &#x2212;20 to &#x2212;100% from the baseline in a patient with atopic dermatitis, for example moderate to severe atopic dermatitis (in particular poorly controlled moderate to severe atopic dermatitis) by parenteral administration of a treatment cycle comprising a dose in the range 200 mg to 600 mg of an antibody, antigen binding fragment thereof or a pharmaceutical formulation thereof , which is an inhibitor of signalling through of the IL-13R&#x3b1;1 by binding the said receptor.</claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. A method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein reduction in EASI is present after about two weeks from administration of the first dose (such as day 15).</claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. A method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein reduction in EASI is present after about four weeks from administration of the first dose (day 29).</claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. A method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein reduction in EASI is present after about six weeks from administration of the first dose (such as day 43).</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. A method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein reduction in EASI is present after about eight weeks from administration of the first dose (such as day 57).</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. A method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein multiple doses are administered in a treatment cycle.</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. A method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein multiple treatment cycles are administered, for example 2, 3, 4 or more treatment cycles are administered.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. A method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein following the treatment cycle or cycles and disease modification, maintenance therapy is administered, for example the same dose administered less frequently (for example monthly), or a lower dose (such as 200 mg) administered the same frequency or less frequently (such as about 2 weekly, about 3 weekly, or about 4 weekly.</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. A method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said antibody or binding fragment thereof is administered approximately weekly, once approx. every 2 weeks, once approximately every 3 weeks, or once approximately every 4 weeks (for example monthly), (in particular a single treatment cycle, especially 8 weeks).</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. A method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein a loading dose in the range 400 to 900 mg, for example 400, 500, 600, 700, 800 or 900 mg is employed before administration of the treatment cycle.</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. A method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the treatment does not comprise a loading dose.</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. A method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the dose is 200 mg.</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. A method according to <claim-ref idref="CLM-00012">claim 12</claim-ref>, wherein the reduction in EASI is in the range &#x2212;15 to &#x2212;60% (for example at about day 15).</claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. A method according to <claim-ref idref="CLM-00012">claim 12</claim-ref>, wherein the reduction in EASI score is in the range &#x2212;40 to &#x2212;85% (eg at about day 29).</claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. A method according to <claim-ref idref="CLM-00012">claim 12</claim-ref>, wherein the reduction in EASI score is in the range &#x2212;25 to &#x2212;85% (eg at about day 43 or 57)</claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. A method according to <claim-ref idref="CLM-00012">claim 12</claim-ref>, wherein the dose is in the range 350 to 450 mg, such as 400 mg, for example wherein 80% of the patient population has an EASI 50 at about day 29 and/or day 57.</claim-text></claim><claim id="CLM-00017" num="00017"><claim-text><b>17</b>. A method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the dose is 600 mg.</claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. A method according to <claim-ref idref="CLM-00017">claim 17</claim-ref>, wherein the reduction in EASI score is in the range &#x2212;25 to &#x2212;60% (eg &#x2212;39 to &#x2212;59, such as &#x2212;40 to &#x2212;59, in particular &#x2212;47, &#x2212;48, &#x2212;49, &#x2212;50, &#x2212;51, &#x2212;52, &#x2212;53, &#x2212;54, &#x2212;55, &#x2212;56, &#x2212;57, &#x2212;58 or &#x2212;59%) for example at about day 15.</claim-text></claim><claim id="CLM-00019" num="00019"><claim-text><b>19</b>. A method according to <claim-ref idref="CLM-00017">claim 17</claim-ref>, wherein the reduction in EASI is in the range &#x2212;50 to &#x2212;100% (eg &#x2212;55 to &#x2212;97%) such as at about day 29.</claim-text></claim><claim id="CLM-00020" num="00020"><claim-text><b>20</b>. A method according to <claim-ref idref="CLM-00017">claim 17</claim-ref>, wherein the reduction in EASI is in the range &#x2212;60 to &#x2212;100% (eg &#x2212;70 to &#x2212;97%) in particular at about day 43.</claim-text></claim><claim id="CLM-00021" num="00021"><claim-text><b>21</b>. A method according to <claim-ref idref="CLM-00017">claim 17</claim-ref>, wherein the reduction in EASI score is in the range &#x2212;65 to &#x2212;100% (for example &#x2212;70 to &#x2212;100, such as &#x2212;90 to &#x2212;100, in particular 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100%) in particular at about day 57.</claim-text></claim><claim id="CLM-00022" num="00022"><claim-text><b>22</b>. A method according to <claim-ref idref="CLM-00017">claim 17</claim-ref>, wherein 90% of the patient population has an EASI 50 at about day 57.</claim-text></claim><claim id="CLM-00023" num="00023"><claim-text><b>23</b>. A method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the treatment cycles comprises a first dose at 600 mg, followed by three weekly doses of 400 mg, e.g. wherein the treatment cycle is repeated twice i.e. two treatment cycles lasting 8 weeks, in particular day 1 600 mg, approx. day 8 400 mg, approx. day 15 400 mg, approx. day 22 400 mg, approx. day 29 600 mg, approx. day 36 400 mg, approx. day 43 400 mg, and approx. day 50 400 mg are administered.</claim-text></claim><claim id="CLM-00024" num="00024"><claim-text><b>24</b>. A method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein disease modification, occurs by day 4, wherein day 1 is the first administration of the antibody or binding fragment thereof, for example wherein the disease modification is a reduction in EASI score, such as wherein the reduction is a percentage from base line in the range &#x2212;10 to 55%.</claim-text></claim><claim id="CLM-00025" num="00025"><claim-text><b>25</b>. A method according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the disease modification in the range &#x2212;40 to &#x2212;100% is achieved by about day 57 following first administration on day 1, e.g. maximum disease modification is achieved by about day 57.</claim-text></claim></claims></us-patent-application>